Inflammation of Innate Immune Responses in the Female Genital Tract: Association with Use of Injectable Progestin-Only Contraception, Reproductive Tract Infections and Risk of HIV Acquisition by Deese, Jennifer
INFLAMMATION OF INNATE IMMUNE RESPONSES IN THE FEMALE GENITAL TRACT: 
ASSOCIATION WITH USE OF INJECTABLE PROGESTIN-ONLY CONTRACEPTION, 
REPRODUCTIVE TRACT INFECTIONS AND RISK OF HIV ACQUISITION 
 
Jennifer Caraway Deese 
 
A dissertation submitted to the faculty of the University of North Carolina at Chapel Hill in partial 
fulfillment of the requirements for the degree of Doctor of Philosophy in the Department of 
Epidemiology in the Gillings School of Global Public Health. 
 
Chapel Hill 
2015 
 
Approved by: 
William Miller 
Frieda Behets 
Myron Cohen 
Charles Morrison 
Doug Taylor 
 
ii 
©2015 
Jennifer Caraway Deese 
ALL RIGHTS RESERVED 
 
iii 
ABSTRACT 
 
Jennifer Caraway Deese: Inflammation of Innate Immune Responses in the Female Genital 
Tract: Association with Sse of Injectable Progestin-Only Contraception, Reproductive Tract 
Infections and Risk of HIV Acquisition 
(Under the direction of William Miller) 
 
 
The successes and failures of many HIV prevention trials, including those of 
microbicides, antiretrovirals and vaccines, have led to a renewed interest in the biological 
mechanisms at the site of HIV infection. In women, the anatomical site of exposure and first 
infection is most often the vaginal and cervical mucosa.[1] Well accepted biological risk factors 
for HIV infection in women include mucosal disruption; immune factors, including the availability 
of CD4+/CCR5+ cells types; sexually transmitted infections (STI) and disturbances in the 
vaginal biome (e.g., bacterial vaginosis (BV)).[2] More recently, the profile of innate immune 
biomarkers – including cytokines, chemokines and antibacterial proteins – and associated levels 
of cellular activation have become a focus of interest as a potential mechanism of increased HIV 
risk.  
The results of prior studies in this area are varied, and additional research is needed. 
Potential reasons for the variability in results includes use of different specimen collection 
methods, methodological and analytical differences, statistical consequences (the increased 
probability of finding significant, yet spurious, associations in the case of measurement of 
multiple outcomes and multiple hypothesis testing) and differential selection of endpoints. 
Stored specimens from FEM-PrEP trial participants offered an opportunity to overcome some of 
the aforementioned challenges in studying the relationship between inflammatory cytokines, 
chemokines and antibacterial proteins with HIV and associated risk factors. 
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FEM-PrEP was a Phase III, randomized, double-blind, placebo-controlled effectiveness and 
safety trial to assess the role of emtricitabine/tenofovir disoproxil fumarate (FTC/TDF, i.e., 
Truvada) in preventing HIV acquisition in women. FEM-PrEP was conducted in Bondo, Kenya; 
Pretoria and Bloemfontein, South Africa; and Arusha, Tanzania.[3] The trial enrolled HIV-
negative women between the ages of 18-35 who met medical and behavioral eligibility criteria 
including being at high risk of HIV. Using stored specimens from the trial we estimated innate 
immune biomarker concentrations among Kenyan and South African women at high risk of HIV 
infection in the absence of known risk factors, and explored the association of those risk factors 
on biomarker concentrations, and analyzed elevated innate immune biomarker concentrations 
as a risk factor for HIV infection in a longitudinal analysis
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CHAPTER 1: SPECIFIC AIMS 
The successes and failures of many HIV prevention trials, including those of 
microbicides, antiretrovirals and vaccines, have led to a renewed interest in the biological 
mechanisms at the site of HIV infection. In women, the anatomical site of exposure and first 
infection is most often the vaginal and cervical mucosa.[1] Well accepted biological risk factors 
for HIV infection in women include mucosal disruption, which may occur via physical or 
chemical disturbance; immune factors, including the availability of CD4+/CCR5+ cells types; 
sexually transmitted infections (STI) and disturbances in the vaginal biome such as with 
bacterial vaginosis (BV).[2] More recently, the profile of innate immune biomarkers – including 
cytokines, chemokines and antibacterial proteins – and associated levels of cellular activation 
have become a focus of interest as a potential mechanism of increased HIV risk.  
The results of many studies of the relationship between innate immune biomarkers and 
HIV risk are quite varied, and additional research is needed. There are a plethora of potential 
reasons for the variable results including, but not limited to, 1) specimen variability (differences 
in collection timing, preparation and storage), 2) use of different assays, 3) methodological 
differences including varying exposure and outcome definitions and differential control of 
confounders, 4) statistical consequences – the increased probability of finding significant, yet 
spurious, associations in the case of measurement of multiple outcomes and multiple 
hypothesis testing and 5) a large number of innate immune biomarkers that are costly to 
measure resulting in differential selection of endpoints by different study teams. 
Stored specimens from FEM-PrEP trial participants offered an opportunity to overcome 
some of the aforementioned challenges in studying the relationship between inflammatory 
cytokines, chemokines and antibacterial proteins and HIV.[3] FEM-PrEP was a Phase III,
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randomized, double-blind, placebo-controlled effectiveness and safety trial to assess the role of 
emtricitabine/tenofovir disoproxil fumarate (FTC/TDF, i.e., Truvada) in preventing HIV 
acquisition in women. FEM-PrEP was conducted in Bondo, Kenya; Pretoria and Bloemfontein, 
South Africa; and Arusha, Tanzania. The trial enrolled HIV-negative women between the ages 
of 18-35 who met medical and behavioral eligibility criteria including being at high risk of HIV.  
Using stored specimens from the trial we estimated innate immune biomarker concentrations 
among Kenyan and South African women at high risk of HIV infection in the absence of known 
risk factors for HIV, and explored the association of those risk factors on biomarker 
concentrations, and analyzed elevated innate immune biomarker concentrations as a risk factor 
for HIV infection in a longitudinal analysis.  
The innate immune markers selected for this analysis were informed by prior research 
which demonstrated variability in concentrations of these markers to be associated with 
injectable progestin-only contraceptive (IPC) use and with risk of HIV infection.[4, 5] This 
research was designed to further elucidate whether there are significant differences in genital 
tract innate immune profiles among women with different risk factors for HIV infection (i.e., IPC 
use and reproductive tract infections (RTI)) and to determine if higher concentrations of innate 
immune biomarkers are associated with increased risk of HIV infection. The results of this 
research will provide insight into potential mechanisms of increased risk of HIV infection among 
women using IPC and may be useful in informing safety evaluations of existing and future HIV 
prevention products and other medical technologies. 
AIM 1: Cross sectional analysis of the association between selected immune biomarkers, 
injectable progestin-only contraception and RTIs 
 
Hypotheses: 
Primary exposure:   
Depot medroxyprogesterone acetate (DMPA) use for ≥ 3 months: We hypothesized that women 
who were using DMPA ≥ 3 months would have higher median concentrations of all measured 
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cytokines and lower median secretory leukocyte peptidase inhibitor (SLPI) concentration as 
compared to the reference population. 
Secondary exposures: 
1. Norethisterone oenanthate (NET-EN) use ≥3 months: We did not anticipate any differences 
in exposure and outcome variables among users of NET-EN as compared to the reference 
population. 
2. Gonorrhea: We hypothesized that women with Neisseria gonorrhoeae (NG) infection would 
have higher median concentrations of all measured cytokines and lower median SLPI 
concentration as compared to the reference population. 
3. Chlamydia: We hypothesized that women with Chlamydia trachomatis (CT) infection would 
have higher median concentrations of all measured cytokines and lower median SLPI 
concentration as compared to the reference population. 
4. Trichomoniasis and BV: We hypothesized that women with Trichomonas vaginalis (TV) 
infection and BV would have higher median concentrations of all measured cytokines and 
lower median SLPI concentration as compared to the reference population. 
5. Intermediate vaginal flora (Nugent score 4-6): We hypothesized that women with 
intermediate vaginal flora (IVF) would have higher median concentrations of all measured 
cytokines and lower median SLPI concentration as compared to the reference population. 
6. BV (Nugent score 7-10): We hypothesized that women with BV would have higher median 
concentrations of all measured cytokines and lower median SLPI concentration as 
compared to the reference population. 
Overview: Selected innate immune biomarker concentrations (cytokines: macrophage 
inflammatory protein (MIP)-1α, MIP-1β, interleukin (IL)-6, IL-8, IL-1α, IL-1β, interferon gamma-
induced protein (IP)-10, regulated and normal T cell expressed and secreted (RANTES), 
granulocyte macrophage colony-stimulating factor (GM-CSF) and antibacterial protein: SLPI) 
were estimated in cervical swab eluents (originally obtained for baseline CT/NG testing) from 
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Kenyan and South African women. We analyzed the association between the selected 
biomarkers and IPC use (including both DMPA and NET-EN) and RTIs (including NG, CT, TV, 
IVF and BV).  We also evaluated differences in markers by age and study site. 
  
AIM 2: Case-cohort analysis of innate immune inflammation as a risk factor for HIV 
acquisition 
 
Hypothesis: We hypothesized that overall innate immune inflammation would be positively 
associated with the risk of HIV infection. 
Overview: A case-cohort study was done to analyze the association between selected innate 
immune biomarker concentrations (cytokines: MIP-1α, MIP-1β, IL-6, IL-8, IL-1α, IL-1β, IP-10, 
GM-CSF and RANTES and antibacterial protein: SLPI) and risk of HIV infection among a high-
risk population of Kenyan and South African women. Cases are all individuals who became HIV 
infected between enrollment in the clinical trial through 60 weeks of follow-up. Fifteen percent of 
the total enrolled cohort was selected as a sub-cohort for independent analyses by FHI 360 and 
were used for this analysis. 
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CHAPTER 2: BACKGROUND AND SIGNIFICANCE 
Globally, women continue to experience a disproportionate burden of HIV compared to 
men.[6] In sub-Saharan Africa, the epicenter of the AIDS epidemic, women account for 58% of 
total HIV infections, and among women, young women (aged15-24) experience the highest 
rates of HIV infection. While dramatic gains have been made over the last decade in reducing 
HIV incidence in many countries, including among women, through increased delivery of 
prevention programs, antiretrovirals to HIV infected individuals which reduces transmission, 
implementation of adult male circumcision programs and other interventions, the total number of 
new HIV infections remains unacceptably high. 
The underlying cause of higher HIV incidence rates among women as compared to men 
are a result of a complex set of social, behavioral and biological determinants that vary by 
region, and within regions, by populations defined by those determinants. These determinants 
range from socioeconomic and gender inequalities to biological differences in men and women 
that render women more susceptible to infection. Understanding the determinants of disease – 
at all levels – is necessary for designing optimal public health interventions. 
In recent years, a number of large clinical trials have been done to evaluate the 
effectiveness of numerous novel biomedical interventions – including, but not limited to, topical 
microbicides with various mechanisms of action, vaccines, treatment as prevention (TasP) and 
oral pre-exposure prophylaxis (PrEP) – for the prevention of HIV acquisition. While some of 
these trials were successful in identifying new approaches to reducing rates of HIV 
transmission, many trials were unsuccessful.[3, 7-13] Nonetheless, the “failed” trials have 
provided new insight into biological (and behavioral) factors that may influence population 
effectiveness of biologically efficacious interventions. Innate immune inflammation in the female
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genital compartment is one of the potential modifiers of intervention effectiveness identified in 
prior trials.[5, 14] 
Sexual HIV transmission in women and innate immunity 
The majority of sexual HIV transmissions in women are believed to occur in the lower 
reproductive tract which includes the ectocervix and vagina.[1, 15] Well accepted 
vaginal/cervical biological risk factors for HIV infection include mucosal disruption, which may 
occur via physical or chemical disturbance; immune factors, including the availability of target 
cell types; genital co-infections (which likely increase risk through the aforementioned and 
additional mechanisms); and disturbances in the vaginal biome such as with BV.[2]   
Successful establishment of HIV infection requires transmission across the multi-layered 
squamous epithelium of the vaginal mucosa, infection of innate immune cells, which likely first 
include Langerhans’ cells (LC) and macrophages, which stimulates an influx of CD4+ T cells, 
the primary cell target of HIV. These target cells are recruited to the focal area of infection by 
secretion of cytokines – chemical messengers that function at mucosal surfaces to regulate 
differentiation, maturation and recruitment of lymphocytes - by infected innate immune cells[16] 
It is hypothesized that rapid recruitment of target cells to the site of exposure, accompanied by a 
slower response by more effective immune mechanisms (e.g., natural killer cell, humoral 
immune responses) may facilitate, rather than inhibit, HIV infection in a process that has been 
described as “too little too late”.[1]  
Expanding on this theory, several recent studies have begun to evaluate the association 
of various innate immune markers and potential risk factors for HIV infection – including, but not 
limited to, age, contraceptive use, prevalent STI and vaginal discharge.[4, 17, 18]  In addition, a 
few studies have also looked at the levels of innate immune factors as independent risk factors 
for HIV acquisition.[5, 18, 19]  
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Injectable progestin-only contraception, HIV and innate immune markers 
  The impact of IPC on HIV acquisition risk remains unclear.[20, 21]  DMPA has long been 
associated with an increased risk of HIV infection in observational epidemiological studies and 
most recently, in two meta-analyses, one which pooled individual participant data from >37,000 
women.[22-26] However, other studies, some of which were included in the aforementioned 
meta-analysis, have found no such significant association.[21, 27-31] While the recent meta-
analyses provide robust evidence, the inability to definitively untangle contraceptive use from 
associated risk behaviors (e.g., condom use) using observational methods has left open the 
possibility of unmeasured confounding. As such, a large randomized controlled trial on the topic 
is currently in planning.[32] The association of NET-EN use and HIV risk is also unclear, but has 
received much less attention.[23, 29, 31, 33, 34] The potential increased risk of HIV infection 
among DMPA users has been attributed to multiple potential causes including behavioral 
differences in DMPA vs. non-DMPA users, vaginal thinning, modification of RTI risk and both 
mucosal innate immune inflammation and suppression which are illustrated in Figure 2.1.[26, 
35] 
The majority of studies on the immunomodulatory effects of DMPA have been conducted 
in vitro using both human and mouse cell lines, and in vivo in macaques, with a predominant 
focus on IFN-γ production, establishment of HIV infection, post-infection viral load, viral diversity 
and antibody production. These studies are by necessity among small numbers of subjects with 
limited statistical power.[36-41] The relevance of in vitro and macaque studies to in vivo human 
responses is difficult to assess. Moreover, most studies that have been done in humans have 
evaluated immune responses in circulating plasmacytoid dendritic cells (pDC) and activated T 
cells in peripheral blood mononuclear cells and several studies have shown divergent innate 
immune responses in the systemic vs. female genital compartments.[36, 42] 
Data from studies which analyze locally relevant specimens from the human female 
genital tract are limited. A recently published study by Guthrie which focused on cationic 
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polypeptides with reported antiviral activity found that DMPA users has significantly higher mean 
levels of human neutrophil peptides (HNP) 1-3 and human cathelicidin-related antimicrobial 
peptide 18 (LL-37) and lactoferrin as compared to non-users of HC.[43] The authors suggest 
that the seemingly contradictory finding of increased levels of proteins with antiviral activity 
among DMPA users could be explained by the unknown cumulative effects of these markers, 
and their complex interactions with other unmeasured markers. Another large study among 832 
women in Zimbabwe and Uganda found that DMPA users had significantly higher RANTES and 
lower beta-defensin 2 (BD-2) as compared to non-HC users.[4] Research to better understand 
the biological associations of the innate immune system and HIV at the site of exposure and 
infection are needed to clarify the observed association of higher rates of HIV acquisition among 
DMPA users. If DMPA users are definitively found to have a higher increased biological risk of 
HIV infection, data from such biological studies could be used in future safety evaluations HIV 
prevention technologies and new and existing contraceptive methods.[35] 
Reproductive tract infections, HIV and innate immune markers 
Mucosal disruption is a well-accepted mechanism of increased risk of HIV infection 
among individuals with STI, particularly ulcerative STIs.[2]  Other mechanisms include both 
immune changes and alterations of the genital microbiome. Recent work undertaken in South 
African HIV-uninfected women to characterize innate immune marker concentrations found 
unique cytokine signatures for different RTIs. Importantly, only 19% of women who had ≥ 1 RTI 
were symptomatic, in a setting in which syndromic diagnosis is the predominant approach to 
STI management, leaving the majority of women with RTI – and therefore at increased risk of 
HIV infection – undiagnosed. Further characterization of innate immune characteristics among 
women with RTI could be used in the development of less expensive screening tools for use in 
settings where pathogen-specific tests are cost-prohibitive and would provide more basic insight 
into the risk of HIV infection among women with RTI. 
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Innate immune markers and HIV acquisition – preclinical evidence 
Published reviews of early biological events during HIV infection and studies in 
macaques provide perhaps the clearest picture on the relationship between innate immune 
activation of cytokines and HIV. Macaque models provide the advantage of known exposure 
dose and time and the ability to take strategically timed pre- and post-infection specimens. 
Though the model has many advantages over human studies, it is important to acknowledge 
that it does not perfectly represent human infection – significantly higher virus doses have often 
been used as compared to levels women are exposed to during vaginal sex, cell-free virus is 
used for inoculation in macaques whereas cell-free and cell-associated virus exposure occurs in 
humans, macaques are often treated with DMPA to thin the vaginal epithelium (which, as 
described above, may also cause other unknown physiologic and immunologic changes) and 
the natural vaginal biome differs between macaques and humans.[1] 
The hypothesis of inflammatory cytokine and chemokine elevation as a risk factor for 
HIV infection is well grounded in basic biology and supportive preclinical studies.[1, 19, 44, 45] 
Prior to HIV exposure, a limited number of activated CD4+ T cells, the principal target cell-type 
of early HIV-1 infection, are readily available at the mucosal surface. They exist primarily in low 
density underneath the epithelium and in deeper sub-mucosal layers (Figure 2.2).[1] Macaque 
studies have demonstrated that simian immunodeficiency virus (SIV) exploits the innate immune 
system to increase the availability of target cells.[1, 19] Upon exposure to HIV, the mucosa 
immediately engages in signaling activities that serve to both inhibit and propagate infection. 
Signaling begins with epithelial cell expression of the chemokine MIP-3α resulting in the 
recruitment of pDC. The pDCs express MIP-1α and MIP-1β which in turn recruit CD4+ T cells, 
part of the innate immune system ordinarily central to an effective immune response, but in the 
case of HIV, also the principal target of early infection.[1, 19, 46] As a result, the initial immune 
response likely provides some level of local viral control (e.g., MIP-1α and MIP-1β block CCR5 
receptors on CD4+ T cells thereby preventing attachment of HIV), though, coupled with an 
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adaptive immune response that is too late, insufficient to prevent spread to distant mucosal and 
lymphoid tissues.[44] 
By extension of the aforementioned biology, numerous conditions which cause an 
increase in the inflammatory status of the genital tract could therefore theoretically increase 
susceptibility to HIV infection including, but not limited to, STIs, altered vaginal flora, sexual 
behavior and contraceptive use.  
Innate immune markers and HIV acquisition – clinical evidence 
Data from CAPRISA 004, a randomized controlled trial conducted in Durban, South 
Africa to evaluate the effectiveness of tenofovir vaginal gel for HIV prevention, when used 
before and after sex, suggest that genital tract elevation of MIP-1α and MIP-1β are associated 
with increased risk of HIV infection (after adjustment for age and tenofovir gel use).[5] Among 
women who became HIV infected during the trial, there was a statistically significant correlation 
in pre- and post-HIV infection cytokine elevation after adjusting for multiple comparisons (IL-1α, 
IL-1β, IL-6, TNF-α, MIP-1β, MCP-1 and IL-7). In a crude analysis not adjusted for tenofovir gel 
use, the incidence rate ratio (IRR) for women with and without increased cytokine levels was 2.1 
(95% CI 0.9-5.3). In addition, the data suggest that elevated cytokines may modify the 
effectiveness of tenofovir gel (IR 0.0 vs. 18.8). These sub-analyses however were limited by 
small sample sizes, notably with cell sizes of zero in some cases. 
In a separate analysis using plasma samples from the same population, a variety of 
immune markers were measured in a case control analysis including 13 cytokines (GM-CSF, 
IFN-γ, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12p70, IL-13 and TNF-α).[14] TNF-α, 
IL-2, IL-7 and IL-12p70 were all significantly associated with HIV risk when comparing cases to 
controls. There were significant limitations to the design of this study however, including a case: 
control ratio <1, control selection based on a self-reported sexual behavior variable which could 
plausibly be related to exposure, different selection criteria for cases and controls (leading to 
substantial demographic and behavioral differences in cases and controls), lack of explanation 
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of confounder selection and possible unmeasured confounding (e.g., no data on STIs were 
included in the final model). Although the results are interesting, the design limitations of this 
study are substantial and additional research is necessary to confirm the results. 
A well designed, large secondary analysis of women in Zimbabwe and Uganda who 
participated in a trial designed to compare the effect of DMPA, combined oral contraceptives 
(COC) and non-hormonal contraceptives on HIV acquisition provide additional insight into 
inflammation and HIV risk.[4] 199 women who became HIV infected during the study were 
matched to 633 uninfected women on the visit immediately preceding seroconversion 
(scheduled visits occurred every three months), study site, age and STI status (positive defined 
as having CT, NG and/or BV). Overall, a statistically significant increase in RANTES and 
decrease in SLPI were associated with HIV seroconversion at the next visit. Notably, this is the 
previously described study which also found an increase in RANTES and lower BD-2 among 
DMPA users. 
Summary 
In summary, a better understanding of the innate immune factors that are associated 
with known and potential risk factors for HIV infection, such as DMPA use and RTIs, as well as 
innate immune inflammation that may exist in the absence of such risk factors, will improve our 
understanding of the determinants of HIV infection at the site of exposure. A complete 
understanding of such determinants could be useful in multiple ways, including but potentially 
not limited to, 1) the safety evaluation of existing and novel technologies that may have an 
impact on the local immune environment, 2) in designing better screening tools for RTI 
detection, and thereby identify individuals in need of treatment, and 3) to understand any 
modification of the effectiveness of novel HIV prevention technologies by the innate 
environment. 
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Table 2.1 Names and functions of selected cytokines [1, 46, 47] 
Cytokine Function  
Inflammatory 
IL-1α 
A member of the interleukin 1 cytokine family. Involved in various immune 
responses, inflammatory responses and hematopoiesis.  Produced by 
monocytes and macrophages in response to cell injury and induced 
apoptosis. 
IL-1β 
A member of the interleukin 1 cytokine family. Mediator of the inflammatory 
response, involved in numerous cellular activities including cellular 
proliferation, differentiation and apoptosis. 
IL-6 Functions in inflammation and the maturation of B cells, recruits neutrophils, dendritic cells, macrophages and lymphocytes. 
Chemokines 
IP-10 
A member of the CXC subfamily and ligand for the receptor CXCR3. Binding 
of this protein to CXCR3 results in pleiotropic effects, including stimulation of 
monocytes, natural killer and T-cell migration, and modulation of adhesion 
molecule expression. 
MIP-1α/CCL3 
Important in the early inflammatory response for activation and recruitment 
of multiple innate and adaptive effector cells to the site of virus entry. Plays 
a role in inflammatory responses through binding to the receptors CCR1, 
CCR4 and CCR5. Polymorphisms at this locus are associated with 
susceptibility and resistance to HIV-1 infection. Expressed by plasmacytoid 
dendritic cells.  
MIP-1β/CCL4 Expressed by plasmacytoid dendritic cells, recruits CCR5+ CD4 T cells and blocks the CCR5 co-receptor on CD4+ T cells. 
IL-8 
Secreted by multiple cell types and a major mediator of the inflammatory 
response through recruitment of neutrophils, dendritic cells, macrophages 
and lymphocytes. 
RANTES 
Displays chemotactic activity for blood monocytes, memory T helper cells 
and eosinophils, is one of the major HIV-suppressive factors produced by 
CD8+ cells as a natural ligand for the chemokine receptor CCR5 which 
thereby suppresses in vitro replication of the R5 strains of HIV-1. 
Hematopoietic 
GM-CSF 
Stimulates growth and differentiation of hematopoietic precursor cells from 
various lineages, including granulocytes, macrophages, eosinophils and 
erythrocytes. 
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Figure 2.1 Biological mechanisms that may contribute to an increased risk of HIV acquisition 
and transmission among women using hormonal contraceptives such as DMPA 
 
Figure and text taken directly from Murphy 2014 
(1) Thinning of the epithelial barrier 
(2) Disruption of intracellular junctional complexes 
(3) Upregulation of Trojan horse receptors that capture HIV particles 
(4) Increased secretion of inflammatory mediators that recruit or activate immune target 
cells and/or facilitate HIV replication 
(5) Decreased secretion of antimicrobial peptides (e.g., SLPI, defensins) that contribute to 
soluble host defense 
(6) Increases CCR5 expression on CD4+ cells rendering the cells more susceptible to HIV 
(7) Increased BV-associated bacteria 
(8) Decreased hydrogen peroxide producing lactobacilli 
(9) Increased genital herpes shedding or clinical lesions with associated disruption of the 
epithelial barrier
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Figure 2.2 Inflammation, innate immunity, mucosal epithelial signaling and target cell availability 
at mucosal front lines 
 
   Figure taken directly from Haase 2010. 
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CHAPTER 3: RESEARCH DESIGN AND METHODS 
Aim 1: Cross sectional analysis of selected innate immune biomarkers and their 
association with progestin-only contraceptive use and reproductive tract infections 
among high risk population 
 
Study Design 
A cross-sectional design was used to estimate innate immune biomarker concentrations 
(cytokines: MIP-1α, MIP-1β, IL-6, IL-8, IP-10, IL-1α, IL-1β and RANTES and antibacterial 
protein: SLPI) among a selection of women categorized into single risk-factor exposure groups. 
The large size of the population screened for the FEM-PrEP trial provided a unique opportunity 
to evaluate associations between selected exposures and outcomes in subpopulations of 
participants without other potential confounding factors. Because genital samples were only 
uniformly collected at screening, only a cross-sectional analysis was possible for this aim.  
While this information does not provide evidence on the causal nature of the relationship 
between these exposures and the selected innate immune markers, they provide additional data 
for hypothesis generation in this data-limited area of HIV prevention. 
Study Population 
Women who were screened for the FEM-PrEP clinical trial in the Bondo, Kenya and 
Pretoria, South Africa sites and met the following criteria were eligible for sampling: 
 Not menstruating (genital specimens not collected from menstruating women) 
 Had valid screening HIV test results 
 Had valid screening STI results (including NG, CT and TV) 
 Had valid screening Nugent score results 
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 Was using DMPA, NET-EN, a non-hormonal contraceptive method or no contraceptive 
method at screening 
o If using DMPA or NET-EN at screening, she must have been using the method 
for ≥3 months 
A total of 508 women were selected for this analysis, among whom 376 had stored 
specimens available for analysis. Women without and with characteristics suggested by 
previous research to be covariates of innate immune biomarker concentrations and HIV risk 
were selected (i.e., women using DMPA or NET-EN, and women with a STI or BV). This 
approach allowed for direct comparison of the Kenya and South Africa immune profiles in the 
absence of potentially important confounding factors and provided a reference population to 
which ‘risk-factor’ populations could be compared to analyze the association between innate 
immune elevation and various risk factors for HIV.  
Exposure Assessment 
A reference population of 99 women who reported not currently using HC and who were 
NG/CT/TV negative and had normal vaginal flora by Nugent score (hereafter referred to as RTI 
negative) was identified for comparison to seven ‘risk-groups’. 
Seven ‘risk-groups’ were defined as follows:  
1) DMPA (n=75) - women who self-reported having used DMPA within the past three months 
and who were RTI negative 
2) NET-EN (n=37) - women who self-reported having used NET-EN within the past three 
months and who were RTI negative  
3) NG (n=15) – women who were positive for Neisseria gonorrhoeae by laboratory testing, self-
reported no use of HC and were otherwise RTI negative 
4) CT (n=22) - women who were positive for Chlamydia trachomatis by laboratory testing, self-
reported no use of HC and were otherwise RTI negative 
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5) TV + BV (n=27) - women who were positive for Trichomonas vaginalis by laboratory testing 
and had bacterial vaginosis by Nugent score, self-reported no use of HC and were 
otherwise RTI negative 
6) IVF (n=28) – women who had IVF by Nugent score, self-reported no use of HC and were 
otherwise RTI negative  
7) BV (n=73) - women who had BV by Nugent score, self-reported no use of HC and were 
otherwise RTI negative 
Notes: 
 There were an insufficient number of participants with Trichmoniasis and no other covariates 
(n=3) for analysis of TV as a single exposure. The majority of participants with 
Trichomoniasis infection at baseline had comorbid BV, therefore, only a combined category 
of Trichomoniasis + BV could be analyzed. 
 Syphilis testing was done at baseline in the trial; however, low prevalence precluded 
analysis of syphilis as a single exposure group.  
Age was self-reported by participants at baseline. Participants were required to use an 
effective contraceptive method (defined as oral contraceptive pills (OC), injectables [DMPA or 
NET-EN], implant, intrauterine device (IUD) or have been previously sterilized) to meet trial 
eligibility criteria; the most frequently used contraceptive methods (i.e., OCs, injectables) were 
provided at the study sites. Contraceptive use was documented at baseline and during follow-up 
visits; injection dates were recorded for injectable methods. RTIs, including NG, CT, TV, BV and 
syphilis and were diagnosed by laboratory testing and treated at baseline. All data were 
recorded on standard trial case report forms. 
Outcome Assessment 
 The following immune markers were quantified in stored endocervical specimens: MIP-
1α, MIP-1β, IL-6, IL-8, IL-1α, IL-1β, IP-10, RANTES, GM-CSF and SLPI. 
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Confounder Assessment 
 Prostate-specific antigen (PSA) testing was done to control for recent unprotected 
semen exposure.  PSA testing was conducted using the Seratec © PSA semiquant assay 
(Seratec Diagnostica, Göttingen, Germany).  Sex without a condom in the past seven days was 
self-reported by participants.  Candida was detected using wet mount and microscopy. 
Statistical Analysis 
Reliability and reproducibility of cytokine and SLPI readings were assessed using 
Spearman’s rank correlation.  Cytokine and SLPI concentrations were calculated as the mean of 
duplicate samples from the same plate.  For cases in which one observation was detectable and 
the second observation was below the limit of detection, the observed concentration was used.  
For cases in which both observations were below the lower limit of detection, the lower limit of 
detection was imputed.  The associations between PSA detection and exposure and outcome 
variables were assessed using Fisher’s exact and Wilcoxon-Mann-Whitney tests.  Exposure-
outcome bivariate associations were assessed using Wilcoxon-Mann-Whitney tests and general 
linear models, controlling for PSA detection (as a marker of recent semen exposure), self-
reported sex without a condom in the past seven days and the presence of candida.  All 
analyses were done using SAS® software version 9.3 (SAS Institute, Cary, NC).[48] 
 
Aim 2: Case-cohort analysis of selected immune biomarkers as risk factors for HIV 
infection 
 
Study Design 
A case-cohort design was employed for Aim 2 to analyze the association of selected 
innate immune biomarkers and risk of HIV infection. The cost of conducting cytokine analyses 
on specimens of the entire cohort was cost-prohibitive; therefore, feasible design approaches 
for this aim were a case-cohort or case-control design. A case-cohort design was selected over 
the case-control design as more extensive potential confounder information is available from a 
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pre-existing case-cohort sample. All cases and a 15% sub-cohort of the entire study population 
were previously selected to analyze the association between HIV infection and Truvada 
(tenofovir and emtricitabine) plasma and intracellular drug levels. Use of this existing case-
cohort sample provided the opportunity to control for time-varying Truvada exposure. In 
addition, a comprehensive review of the literature suggested the following variables as potential 
confounders of the effect of innate immune elevation on HIV risk: age, DMPA use, RTI and site 
(as a proxy variable for local STI/HIV prevalence). The relationships between the exposure, 
outcome and covariates is presented in Figure 3.1 in the form of a Directed Acyclic Graph. 
Study Population 
Women who were enrolled in the FEM-PrEP clinical trial in the Bondo, Kenya and Pretoria, 
South Africa sites and met the following criteria were eligible for inclusion: 
 Did not have a positive HIV RNA or DNA PCR result on the enrollment sample 
 Sub-cohort: A 15% random sample of the entire enrolled study cohort 
 Cases: all participants with incident HIV infection defined as having initial and 
confirmatory HIV positive antibody results according to the trial testing algorithm 
between enrollment and 60 weeks of follow-up and having been confirmed as an 
incident HIV case according to confirmatory testing at the Institute of Tropical Medicine 
in Belgium 
Exposure Assessment 
 The following immune markers were quantified in stored endocervical specimens: MIP-
1α, MIP-1β, IL-6, IL-8, IL-1α, IL-1β, IP-10, RANTES, GM-CSF and SLPI. 
Outcome Assessment 
 HIV testing was conducted every four weeks from trial enrollment through 60 weeks of 
follow-up using a standardized rapid test algorithm; results were recorded on standardized case 
report forms. Confirmatory testing was done at the Institute of Tropical Medicine in Belgium on 
specimens from women who had positive antibody results according to the rapid algorithm.  
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Time to HIV infection was defined as the time between enrollment and date of collection of the 
first specimen which was HIV RNA and/or DNA positive. 
Statistical Analysis 
 Reliability and reproducibility of cytokine and SLPI readings were assessed using 
Spearman’s rank correlation. Cytokine concentrations were calculated as the mean of duplicate 
samples from the same plate, the mean of duplicate samples from separate plates if one 
observation was undetectable on the plate with duplicate specimens, the observed 
concentration if only 1/3 readings was detectable and the median value between zero and the 
lowest observed standard if all three observations were undetectable. SLPI concentrations were 
calculated as the mean of duplicate readings; if both observations were below the limit of 
detection, the midpoint between zero and the lower limit of detection was imputed, if both 
observations were above the limit of detection, the upper limit of detection was imputed.   
Cytokines and SLPI were analyzed in multivariate models as: 1) ten dichotomous variables (one 
per marker), and 2) a single dichotomous summary variable of inflammation (cytokines) and a 
separate dichotomous variable for SLPI (< or ≥ the median concentration). For the former, 
individual marker concentrations were dichotomously coded as < or ≥ the median concentration.  
For the latter, an intermediate summary variable was set equal to the number of cytokines ≥ the 
median concentration (range 0-9) per woman. The median of the intermediate summary 
variable was then defined as the cut point for the final dichotomous inflammation variable. 
Missing covariate data was handled as follows: 1) RTI/STI pelvic exam data were used to 
impute missing results based on syndromic management assessment, 2) contraceptive method 
was carried forward from the previous non-missing visit, 3) FTC/TDF use was carried forward 
from the previous non-missing visit. FTC/TDF use was coded as no/low among all women in the 
placebo arm. 
Bivariate associations between immune markers and HIV infection were assessed using 
Wilcoxon-Mann-Whitney tests. A Cox-proportional hazard model with pseudo-likelihood and 
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robust variance was used to model the association between immune marker concentrations and 
risk of HIV infection over time.[49-51]  Age and RTI/STI were fixed at baseline whereas 
contraceptive method and FTC/TDF use were time-varying. Covariates were evaluated as 
potential effect measure modifiers with retention of covariates pre-specified for likelihood ratio 
tests resulting in p<0.20.  Covariates that resulted in >10% change in the hazard ratio through 
backwards selection were retained in the final model. All analyses were done using SAS® 
software version 9.3 (SAS Institute, Cary, NC).[48] 
Laboratory Methods 
The laboratory methods described here, with the exception of TFV and TFV-DP detection which 
are only applicable to Aim 2, are applicable to both Aims 1 and 2. 
 Sterile synthetic swabs were collected and eluted in 1000-1200µL phosphate buffered 
saline (PBS) and the volume which remained after NG/CT testing was stored at -70⁰C during 
the FEM-PrEP trial (between May 2009 and November 2010). Cytokine and SLPI testing was 
conducted on these stored aliquots between July 2012 and April 2013. Cytokine concentrations 
were measured using MilliplexTM Human Cytokine kits (Millipore, MA, USA) on a Bio-PlexTM 
Suspension Array Reader (Bio-Rad Laboratories Inc®, CA, USA) according to a written 
standard operating procedure in accordance with manufacturer instructions; specimens were 
pre-filtered by centrifugation using 0.2µm cellulose acetate filters (Sigma-Aldrich, USA) to 
ensure mucus did not interfere with the assay and were tested in duplicate on the same plate.  
Each sample was also tested on a second plate in order to evaluate inter-assay reproducibility. 
SLPI concentrations were measured in duplicate using the Quantikine Human SLPI 
Immunoassay kit  from R&D Systems (Minneapolis, MN) by adapting the manufacturer’s 
instructions for vaginal specimens (1:400 in calibrator diluent RDT). Optical densities were read 
at 450 nm with a second reference filter of 570 nm using a Biotek ELx800 reader (Vermont, 
USA) and KCJunior Software. PSA testing was performed using the Seratec © PSA semiquant 
assay (Seratec Diagnostica, Göttingen, Germany). A volume of 120µL of filtrated swab elute 
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was used for testing according to the manufacturer’s instructions with specimens classified as 
negative, low positive or positive.   
RTI testing was done during the trial; CT/NG testing was done using polymerase chain 
reaction (PCR) on the Roche Cobas Amplicor platform, TV was detected using wet mount 
microscopy and BV visualized using Gram staining and Nugent scoring. Tenofovir (TFV) and 
tenofovir diphosphate (TFV-DP) were measured in plasma and upper layer packed cells using 
protein precipitation and LC-MS/MS detection using methods that have been described.[3, 52]  
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Tables and Figures 
Figure 3.1 Directed Acyclic Graph, Aim 2 
 
  
STI/BV 
HIV 
Innate 
immune 
elevation 
Behavior 
Site (proxy for 
local STI/HIV 
prevalence) 
DMPA 
Age 
Truvada use 
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Table 3.1 Determination of minimally sufficient adjustment set, Aim 2 
Path1 Type2 Status3 
Possible 
adjustment 
set4 
IIE  HIV C O  
IIE  Age  HIV NC O A 
IIE  Age  DMPA  HIV NC O A or D 
IIE  Age  DMPA  Site  HIV NC B  
IIE  Age  DMPA  STI  HIV NC O A or D or S 
IIE  Age  DMPA  STI  Site  HIV NC B  
IIE  Age  DMPA  Site  STI  HIV NC B  
IIE  Age  Behavior  STI  HIV NC O A or B or SB 
IIE  DMPA  Age  HIV NC O A or D 
IIE  DMPA  Age  Behavior  HIV NC O A or D or B 
IIE  DMPA  HIV NC O D 
IIE  DMPA  Site  HIV NC O D or S 
IIE  DMPA  Site  STI  HIV NC O D or S or SB 
IIE  DMPA  STI  HIV NC O D or SB 
IIE  DMPA  STI  Site  HIV NC B  
IIE  DMPA  Site  STI  Behavior  HIV NC B  
IIE  DMPA  STI  Behavior  HIV NC B  
IIE  DMPA  Age  Behavior  STI  HIV NC O D or A or B or SB 
IIE  STI  HIV NC O SB 
IIE  STI  Behavior  HIV NC O B or SB 
IIE  STI  Site  DMPA  Age  Behavior  HIV NC B  
IIE  STI  DMPA  Age  Behavior  HIV NC B  
IIE  STI  DMPA  Age  HIV NC B  
IIE  STI  Site  HIV NC O SB or S 
IIE  Behavior  Truvada use  HIV NC O B or T 
IIE  Behavior  STI/BV  Truvada use  HIV NC O B or SB or T 
IIE  Behavior  STI/BV  Site  DMPA  Age  Truvada Use 
 HIV NC B  
IIE  Behavior  STI/BV  DMPA  Age  Truvada use  HIV NC B  
IIE  STI/BV  Behavior  Truvada use  HIV NC O SB or B or T 
IIE  STI/BV  Site  DMPA  Age  Truvada use  HIV NC B  
IIE  DMPA  Age  Truvada use  HIV NC O D or A or T 
IIE  DMPA  Site  STI/BV  Behavior  Truvada use  HIV NC B  
IIE  DMPA  STI/BV  Behavior  Truvada use  HIV NC O D or SB or B or T 
IIE  Age  Truvada use  HIV NC O A or T 
1 IIE = innate immune elevation 
2 C=causal, NC=non-causal 
3 O=open, B=blocked 
4 A=age, D=DMPA, S=site, B=behavior, SB=STI/BV 
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CHAPTER 4: INJECTABLE PROGESTIN-ONLY CONTRACEPTION IS ASSOCIATED WITH 
INCREASED LEVELS OF PRO-INFLAMMATORY CYTOKINES IN THE FEMALE GENITAL 
TRACT 
 
OVERVIEW 
Problem 
Genital inflammatory changes may be a mechanism of increased HIV risk among injectable 
progestin-only contraception (IPC) users. 
Method of Study 
We conducted a cross-sectional analysis of 376 Kenyan and South African women. Genital 
cytokines and secretory leukocyte peptidase inhibitor concentrations in a reference population 
were compared to IPC users and women with RTI. 
Results 
No significant variability in marker concentrations was observed by age or site. Depot 
medroxyprogesterone acetate (DMPA) users had significantly higher MIP-1α, MIP-1β, IL-6, IL-8, 
IP-10 and RANTES concentrations. Norethisterone oenanthate (NET-EN) users had 
significantly higher IL-6, IL-8 and RANTES concentrations. Women with sexually transmitted 
infections had variable inflammation, and women with BV exhibited a mixed phenotype of up 
and downregulation. 
Conclusions 
The finding of substantial mucosal inflammation among DMPA users provides evidence which, 
combined with the results of prior studies, suggests that DMPA may create an immune 
environment conducive to HIV target cell recruitment and inhibitory for antiviral activity.
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INTRODUCTION 
 The successes and failures of many HIV prevention trials, including those of 
microbicides, antiretrovirals and vaccines, have led to great interest in the biology of HIV 
transmission. In heterosexual women, the anatomical site of exposure and first infection is most 
often the vaginal and cervical mucosa.[1] Well-accepted biological cervicovaginal risk factors for 
HIV infection include mucosal epithelial disruption, which may occur via physical or chemical 
disturbance; immune factors, including the availability of CCR5+/CD4+ target T cells; sexually 
transmitted infections (STI); and disturbances in the vaginal microbiota, such as bacterial 
vaginosis (BV).[2]  Depot medroxyprogesterone acetate (DMPA), a progestin-only contraceptive 
injectable (IPC), has also been associated with altered inflammatory responses and increased 
HIV risk although epidemiological studies remain inconclusive.[22, 23] 
 Female genital mucosal inflammation, characterized as increased inflammatory 
cytokines, decreased antibacterial proteins and/or increased target cell activation, has been 
associated both directly and indirectly with increased risk of HIV infection.[4, 53] Several 
immune markers have been evaluated with variable associations with potential risk factors of 
interest (i.e., race, RTIs, age, cervical ectopy, menstrual phase, pregnancy, breastfeeding and 
hormonal contraceptive use).[17, 18, 54, 55] Evaluations of the impact of RTIs on female genital 
cytokine profiles have been limited by use of specimens from previously completed clinical trials 
which lacked available data on potentially important confounders. Furthermore, the impact of 
hormonal contraception (HC) on these inflammatory markers is unclear. We examined cytokine 
and secretory leukocyte peptidase inhibitor (SLPI) profiles among women using IPC, including 
DMPA and norethisterone oenanthate (NET-EN) – a two-monthly injectable progestin, and 
women with RTIs. In this study, we compared these results to a reference group of women not 
using HC and who were free of common RTIs.  
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METHODS 
Design 
 We conducted a cross-sectional study to evaluate the association between genital 
mucosal inflammatory markers, IPC use and RTIs among women screened for the FEM-PrEP 
trial in Pretoria, South Africa and Bondo, Kenya. FEM-PrEP was a Phase III, randomized, 
double-blind, placebo-controlled effectiveness and safety trial to assess the role of 
emtricitabine/tenofovir disoproxil fumarate (FTC/TDF, i.e., Truvada) in preventing HIV 
acquisition in women conducted in Bondo, Kenya; Pretoria and Bloemfontein, South Africa; and 
Arusha, Tanzania.[3] The FEM-PrEP trial uniformly collected and stored endocervical swab 
specimens at the screening visit. Due to the large trial size, we were able to select sub-
populations with single risk factors for comparisons; all ‘risk-groups’ were compared to a 
reference population of women who were not using HC, were STI negative and had normal 
vaginal flora. 
Study population 
 Women who were screened for the FEM-PrEP trial in Bondo, Kenya and Pretoria, South 
Africa were eligible for selection if they had valid screening HIV and RTI test results (including 
Neisseria gonorrhoeae (NG), Chlamydia trachomatis (CT), Trichomonas vaginalis (TV), syphilis 
and BV by Nugent score) and were using DMPA, norethisterone oenanthate (NET-EN), a non-
hormonal contraceptive method or no contraceptive method. All women who had only one of the 
aforementioned potential risk factors for HIV (i.e., use of IPC or a single RTI [with the exception 
of women with TV infection who predominantly had concurrent BV]), and a reference group of 
women were selected yielding a total 376 participants for analysis as follows: 1) reference 
population (no current HC use, RTI negative) n=99, for comparison to the following ‘risk-groups’: 
2a) DMPA group (used DMPA within the past three months, RTI negative) n=75, 2b) NET-EN 
group (used NET-EN within the past three months, RTI negative) n=37, 2c) women with NG (no 
current HC use and otherwise RTI negative) n=15, 2d) women with CT (no current HC use and 
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otherwise RTI negative) n=22, 2e) women with both TV and BV (no current HC use and 
otherwise RTI negative) n=27, 2f) women with intermediate flora (Nugent score 4-6, no current 
HC use and otherwise RTI negative) n=28, and 2g) women with BV (Nugent score 7-10, no 
current HC use and otherwise RTI negative) n=73 (Figure 4.1). Although syphilis testing was 
done at baseline, the low prevalence precluded analysis among women with syphilis. 
Laboratory methods 
 The following immune markers were quantified: macrophage inflammatory protein (MIP)-
1α, MIP-1β, IL-6, IL-8, IL-1α, IL-1β, IP-10, RANTES, granulocyte macrophage colony-
stimulating factor (GM-CSF) and SLPI. Prostate-specific antigen (PSA) testing was also done to 
control for recent semen exposure in statistical analyses.[56]  
 Sterile synthetic swabs were collected and eluted in 1000-1200µL phosphate buffered 
saline (PBS) and the volume which remained after NG/CT testing was stored at -70⁰C during 
the FEM-PrEP trial (between May 2009 and November 2010). Cytokine, SLPI and PSA testing 
were conducted on the stored aliquots between July 2012 and April 2013. Cytokine 
concentrations were measured using MilliplexTM Human Cytokine kits (Millipore, MA, USA) on 
a Bio-PlexTM Suspension Array Reader (Bio-Rad Laboratories Inc®, CA, USA) according to a 
written standard operating procedure in accordance with manufacturer instructions; specimens 
were pre-filtered by centrifugation using 0.2µm cellulose acetate filters (Sigma-Aldrich, USA) to 
ensure mucus did not interfere with the assay and were tested in duplicate on the same plate. 
SLPI concentrations were measured in duplicate using the Quantikine Human SLPI 
Immunoassay kit  from R&D Systems (Minneapolis, MN) by adapting the manufacturer’s 
instructions for vaginal specimens (1:400 in calibrator diluent RDT). Optical densities were read 
at 450 nm with a second reference filter of 570 nm using a Biotek ELx800 reader (Vermont, 
USA) and KCJunior Software. PSA testing was performed using the Seratec © PSA semiquant 
assay (Seratec Diagnostica, Göttingen, Germany). A volume of 120µL of filtrated swab elute 
was used for testing according to the manufacturer’s instructions with specimens classified as 
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negative, low positive or positive. RTI testing was done during the trial; NG/CT testing was done 
using polymerase chain reaction (PCR) on the Roche Cobas Amplicor platform, TV was 
detected using wet mount microscopy and BV visualized using Gram staining and Nugent 
scoring. 
Statistical analysis  
 Reliability and reproducibility of cytokine and SLPI readings were assessed using 
Spearman’s rank correlation. Cytokine and SLPI concentrations were calculated as the mean of 
duplicate samples from the same plate. For cases in which one observation was detectable and 
the second observation was undetectable, the observed concentration was used. For cases in 
which both observations were undetectable, the lower limit of detection was imputed. The 
associations between PSA detection, as a potential confounder, and exposure and outcome 
variables were assessed using Fisher’s exact and Wilcoxon-Mann-Whitney tests. Exposure-
outcome bivariate associations were assessed using Wilcoxon-Mann-Whitney tests and general 
linear models, controlling for PSA detection (as a marker of recent semen exposure), self-
reported sex without a condom in the past seven days and the presence of candida. All 
analyses were done using SAS® software version 9.3 (SAS Institute, Cary, NC).[48]  
 This research was approved by the FHI 360 Protection of Human Subjects Committee 
and the Office of Human Research Ethics at the University of North Carolina at Chapel Hill. Trial 
participants included this analysis provided informed consent during the FEM-PrEP study for 
future research on stored specimens. 
RESULTS 
 Among the 376 non-pregnant, HIV negative women in this analysis, the median age was 
24 years (range 18-35). Women in Bondo were somewhat older than women in Pretoria 
(median 25 vs. 22 years, respectively) and had fewer years of education (median 8 vs. 12). 
Women were more likely to use condoms with other partners (i.e., sex with partners other than 
who the woman considered to be her primary sex partner) vs. primary partners in both sites 
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(Table 4.1), although women in Bondo used condoms less with either partner type as compared 
to women from Pretoria (primary partner mean percentage condom use in the last 7 days 27% 
vs. 40% and ‘other’ partner mean percentage condom use in the last 7 days 52% vs. 68%, 
respectively). Contraceptive use was generally low at the baseline visit (by study design), with 
over half of the population reporting no use of contraception.  With the exception of TV and BV, 
RTIs were more prevalent among women in Pretoria. Herpes simplex virus type 2 (HSV-2) 
testing was only conducted on a subset of women in the parent clinical trial; among women in 
this analysis, HSV-2 data were available for 142 (36%) women from the Pretoria site with 85 
(60%) of those women testing seronegative and 57 (40%) testing seropositive.  
Cytokines and SLPI detection 
 Spearman correlation between intra-plate cytokine concentration readings was generally 
high with all correlation coefficients ≥0.96 with the exception of MIP-1α (0.84).  The validity of 
extrapolated readings was evaluated separately; extrapolated readings remained significantly 
correlated (p≤0.05) for IL-6, IL-8, IL-1β and RANTES (ρ range: 0.85-0.95) although correlation 
was considerably lower for MIP-1α, MIP-1β, IL-1α and IP-10. Cytokine concentrations that were 
below the limit of detection ranged from <1% to 15%. Only one observation for one marker was 
above the limit of detection in this analysis (IL-8). GM-CSF was not included in any analyses 
due to a large number of observations below the detectable range (36%). Correlation between 
duplicate SLPI readings was high (ρ 0.99) and most observations were within the limits of 
detection (98.4%). 
PSA detection 
 We measured PSA to control for contamination with semen. Three-quarters of 
specimens were PSA negative (75%); 15% were classified as positive and 10% as low positive 
indicating that these women had likely engaged in unprotected sexual intercourse within 48 
hours of sample collection.[14, 15] In bivariable analyses, women who were using DMPA 
(p=0.004), had BV (p<0.001) or had any STI or BV (p=0.006) were significantly more likely to be 
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PSA positive. IL-6 (p=0.026), IL-8 (p=0.018) and IL-1β (p=0.042) concentrations were 
significantly lower, and SLPI (p=0.020) concentrations were significantly higher, in specimens 
classified as PSA positive. In subsequent multivariable analyses, we therefore adjusted for PSA 
as a potential confounder with PSA coded dichotomously (low positive and positive collapsed 
into a single positive category). 
Association of inflammatory markers with age and study site 
 Cytokine and SLPI profiles in the reference population of 99 women reporting no HC 
use, and who were NG, CT and TV negative and with normal vaginal flora, did not vary 
significantly when stratified by site or age group (Table 4.2).  
Association of inflammatory markers with injectable progestin-only contraceptive use 
 DMPA users had the highest number of elevated genital inflammatory cytokines; 
concentrations of MIP-1α, MIP-1β, IL-6, IL-8, IP-10 and RANTES were significantly elevated as 
compared to the reference group of women reporting no HC use and who were RTI negative 
(Table 2, Figures 4.2, 4.3, 4.4). Similarly, IL-6, IL-8 and RANTES concentrations were 
significantly higher in NET-En users as compared to the reference population. Adjustment for 
PSA, self-reported sex without a condom in the past seven days and the presence of candida 
had little effect (data not shown). 
Association of inflammatory markers with reproductive tract infections 
 Women with STIs or BV generally had less inflammation compared to DMPA users 
(Table 4.2). Women with NG had significantly higher IL-1α and lower SLPI concentrations, and 
women with CT had significantly higher IP-10 and RANTES concentrations, as compared to the 
reference group. Women who had both TV and had BV had significantly elevated IL-8, IL-1α 
and IL-1β and significantly lower SLPI concentrations. Similarly, women with only BV had 
significantly elevated IL-1α and IL-1β concentrations, as well as significantly lower MIP-1α, MIP-
1β and IP-10 concentrations.  Women with intermediate flora (Nugent score 4-6) also had 
significantly elevated IL-1α and IL-1β, as well as IL-6 and IL-8 concentrations. Adjustment for 
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PSA, self-reported sex without a condom in the past seven days and the presence of candida 
had little effect (data not shown). 
Sensitivity analysis 
 In a sensitivity analysis using available HSV-2 data, there were no significant differences 
in any of the measured immune markers between HSV-2 positive vs. HSV-2 negative women in 
the reference group. Furthermore, the proportion of women who were HSV-2 positive did not 
differ when comparing women between the reference and exposure groups, which suggests the 
results may not be confounded by HSV-2 status. 
DISCUSSION 
 The impact of IPC on HIV acquisition risk remains unclear. DMPA has been associated 
with an increased risk of HIV infection in observational epidemiological studies and most 
recently, in two meta-analyses, one which pooled individual participant data from >37,000 
women.[22, 23] However, other studies, some of which were included in the aforementioned 
meta-analysis, have found no such association.[28-31, 57] Association of NET-EN use and HIV 
risk is also unclear, but has received much less attention.[29, 31, 33, 34]  
 In this evaluation, we controlled for many potential confounders, including RTIs, HIV 
positivity, pregnancy and recent exposure to semen. We observed significant increases in IL-6, 
IL-8 and RANTES among both DMPA and NET-EN users, compared to women without RTIs or 
IPC use. DMPA users also had significantly higher concentrations of MIP-1α, MIP-1β and IP-10.  
The consistent findings among DMPA and NET-EN users suggest high-dose progestin 
exposure is associated with an increase in pro-inflammatory cytokines. These results are 
consistent with a large study of hormonal contraception and HIV in Uganda and Zimbabwe 
which found significant elevation of RANTES among women using DMPA in endocervical 
specimens.[4] Increased concentrations of MIP-1α, MIP-1β, IL-8 and IP-10, which were 
significantly elevated in DMPA-using women in our study, have similarly been associated with 
increased risk of HIV acquisition.[53]  
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 Perhaps surprisingly, women with RTIs had fewer median increases in inflammatory 
cytokines as compared to women using DMPA. Elevated RANTES and IP-10 concentrations 
among CT infected women and IL-1α among NG infected women has been observed 
previously.[55]  With BV, some markers of inflammation were increased and others decreased 
as previously reported.[55, 58] The marked difference in the distributions among women with 
both TV and BV, as compared to the reference population (Figures 4.3, 4.4, 4.5), suggests a 
potential synergistic force on inflammation, and suppression of SLPI, among women with both 
STIs and BV.  A confirmed profile of inflammatory markers associated with RTIs could be used 
in the development of a cost-effective screening tool to improve RTI detection in high 
prevalence settings that rely on syndromic management. 
 The lack of complete HSV-2 data among women in this study many have affected the 
results. However, a recent paper by Masson et al which sought to characterize innate immune 
profiles of women with STIs found no association between HSV-2 status as measured by 
antibody detection in serum or active infection with viral shedding.[55] Further, due to the cross-
sectional design, a causal relationship between the exposures and observed increase in 
inflammatory markers cannot be established. However, the strict inclusion criteria and 
participant sampling approach utilized, along with measurement of PSA to control for recent 
sexual activity, methodologically controls for many potential confounders including pregnancy, 
comorbid RTIs and HIV. 
 In summary, IPC use was associated with increased markers of inflammation in the 
female genital tract.  Such inflammation offers biological plausibility for increased risk of HIV 
acquisition, an ongoing concern for users of these agents.  Given the gravity of this problem, a 
randomized clinical trial to define the role of hormonal contraception in HIV acquisition has been 
planned.[32] 
 Tables and Figures 
Figure 4.1 Flow diagram of participant selection 
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Table 4.1 Study population characteristics 
Table I. Study Population Characteristics 
  
Bondo 
N (%) 
Pretoria 
N (%) 
Total 
N (%) 
Characteristic (N=206) (N=170) (N=376) 
Age    
 18-24 90 (44) 112 (66) 202 (54) 
 25-29 51 (25) 32 (19) 83 (22) 
 30-35 65 (32) 26 (15) 91 (24) 
Sexual behavior    
 Has primary partner 200 (97) 169 (99) 369 (98) 
 Has other partners 105 (51) 30 (18) 135 (36) 
Contraceptive method       
 Depot medroxyprogesterone acetate (DMPA) 62 (30) 13 (8) 75 (20) 
 Norethisterone enanthate (NET-EN) 0 (0) 37 (22) 37 (10) 
 Condoms 19 (9) 7 (4) 26 (7) 
 Female sterilization 10 (5) 2 (1) 12 (3) 
 Other1 4 (2) 0 (0) 4 (1) 
 None 111 (54) 111 (65) 222 (59) 
Reproductive tract infections       
 Chlamydia 1 (<1) 21 (12) 22 (6) 
 Gonorrhea 3 (1) 12 (7) 15 (4) 
 Trichomoniasis 22 (11) 5 (3) 27 (7) 
 Syphilis2 0 (0) 4(2) 4 (1) 
 Bacterial vaginosis3 79 (38) 21 (12) 100 (27) 
 Intermediate vaginal flora4 11 (5) 17 (10) 28 (7) 
 Candida 18 (9) 18 (15) 47 (13) 
 Herpes simplex virus type 25 --- 57 (40%) --- 
1 Two participants reported calendar method, two reported herbal 
2 Syphilis results were not available for 15 participants (6 in Pretoria, 9 in Bondo) 
3 Bacterial vaginosis defined as Nugent Score 7-10 
4 Intermediate vaginal flora defined as Nugent Score 4-6 
5 Herpes simplex virus type 2 results only available for 36% of women (n=142) from the Pretoria site 
 
 
 Table 4.2 Genital protein concentrations (median (IQR), pg/mL) by subgroups 
Table 2. Genital protein concentrations (median (IQR), pg/mL) by subgroup 
  Pro-inflammatory  
 Characteristics MIP-1α MIP-1β IL-6 IL-8 IL-1α IL-1β IP-10 RANTES  
Women without selected covariates (reference population) 
 
Total (n=99) 9 
(3,27) 
15 
(4,33) 
3 
(2,9) 
250 
(92,650) 
27 
(11,65) 
3 
(1, 6) 
33 
(10,116) 
2 
(1,5) 
 
 
By Site   Bondo, Kenya (n=50) 8 
(3,25) 
8 
(3,24) 
3 
(3,9) 
138 
(52,460) 
26 
(11,73) 
3 
(2,4) 
31 
(14,80) 
2 
(1,2) 
 
 
               Pretoria, South Africa 
(n=49) 
11 
(5,29) 
18 
(4,52) 
3 
(2,9) 
465 
(141,928) 
23 
(12,58) 
2 
(1,7) 
38 
(8,244) 
3 
(1,14) 
 
 
By Age   18-24 (n=60) 8 
(3,24) 
10 
(3,37) 
2 
(2,6) 
156 
(77,530) 
22 
(11,45) 
3 
(1,4) 
26 
(9,107) 
2 
(1,5) 
 
 
               Age 25-29 (n=17) 17 
(11,26) 
18 
(16,23)) 
7 
(2,12) 
491 
(166,739) 
28 
(20,77) 
3 
(1,13) 
66 
(21,133) 
2 
(2,3) 
 
 
               Age 30-35 (n=22) (ref) 10 
(3,29) 
11 
(4,35) 
4 
(2,19) 
412 
(118, 974) 
30 
(10,90) 
3 
(1,7) 
44 
(2,86) 
2 
(2,4) 
 
Covariate category (comparator populations) 
 
DMPA use ≥ 3 months (n=75) 24**
(7, 56) 
20*
(10, 51) 
13**
(4, 32) 
617** 
(248, 1511) 
30 
(14, 69) 
3 
(1, 19) 
86**
(33, 236) 
9**
(4, 17) 
 
 
NET-EN use ≥ 3 months (n=37) 19 
(8, 34) 
20 
(10, 33) 
13*
(4, 24) 
632* 
(370, 1013) 
28 
(14, 65) 
3 
(1, 11) 
38 
(13, 293) 
8*
(2, 17) 
 
 
Gonorrhea (n=15) 8 
(5, 38) 
11 
(3, 56) 
4 
(1, 8) 
364 
(127, 1661) 
45*
(30, 225) 
2 
(1, 25) 
18 
(6, 115) 
2 
(1, 7) 
 
 
Chlamydia (n=22) 12 
(6, 19) 
14 
(7, 25) 
9 
(3, 13) 
427 
(174, 770) 
37 
(9, 171) 
2 
(1, 7) 
82*
(25, 380) 
6*
(2, 12) 
 
 
Trichomoniasis + BV (n=27) 7 
(3, 15) 
7 
(4, 16) 
4 
(2, 10) 
749** 
(419, 3208) 
283**
(68, 590) 
39**
(8, 138) 
26 
(19, 40) 
2 
(1, 8) 
 
 
Intermediate flora2 (n=28) 11 
(2, 26) 
15 
(3, 36) 
10*
(3, 37) 
595* 
(268, 1408) 
73**
(41, 213) 
10*
(1, 110) 
42 
(8, 92) 
2 
(1, 16) 
 
 
Bacterial vaginosis2 (n=73) 4*
(2, 17) 
6*
(3, 17) 
5 
(3, 12) 
442 
(65, 1186) 
95**
(58, 266) 
9**
(3, 31) 
14*
(2, 49) 
2 
(1, 4) 
 
* Wilcoxon-Mann-Whitney test significant as compared to the reference population at p≤0.05 
** Wilcoxon-Mann-Whitney test significant as compared to the reference population at p≤0.001 
1 Sample sizes for SLPI analyses varied slightly from cytokine analyses due to SLPI assay failures as follows: DMPA=71, BV=72, ≥ 1 STI 
and/or BV=136 
2 Intermediate flora defined as Nugent Score 4-6; bacterial vaginosis defined as Nugent Score 7-10 
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 Figure 4.2 Inflammatory marker concentrations in reference group and IPC users
 
 
 
 
 
 
 
 
 
 
 
 
 
 
y-axis is concentration of marker in pg/mL.  Top whisker of all plots only extends to the 90th percentile to make central data visible. 
*Wilcoxon-Mann-Whitney test significant as compared to the reference population at p≤0.05 
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Figure 4.3 Total inflammatory markers concentrations by ‘risk group’ 
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Figure 4.4 Total inflammatory markers concentrations by ‘risk group’, removing IL-8 
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Figure 4.5 Total SLPI concentrations by ‘risk group’ 
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CHAPTER 5: INNATE IMMUNITY MARKERS ASSOCIATED WITH HIV ACQUISITION 
AMONG WOMEN AT HIGH RISK 
 
OVERVIEW 
Problem 
Women with genital tract inflammation may be at increased risk of HIV infection independent of 
other known risk factors for HIV acquisition. 
Method of Study 
We conducted a case-cohort study to analyze the association between innate immune factors in 
the female genital tract and HIV acquisition. Women in Kenya and South Africa who became 
HIV infected between enrollment and 60 weeks of follow-up during a clinical trial of Truvada for 
HIV prevention were included as cases. A random sub-cohort of women in the clinical trial was 
selected from individuals who were HIV RNA and DNA PCR negative at enrollment and 
completed at least one follow-up visit.  A Cox model with pseudo likelihood and robust variance 
estimation were used to assess the association of innate immune factors and HIV acquisition. 
Results 
Higher IL-1β and RANTES concentrations were associated with HIV acquisition when including 
women from both the Truvada and placebo arms of the clinical trial. When restricting the 
analysis to women in the placebo group, higher MIP-1α and IL-8 concentrations were also 
associated with HIV acquisition. In a model using a composite variable for innate immune 
inflammation, no association was observed. Coding of innate immunity markers had 
considerable influence over effect estimates in sensitivity analyses. 
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Conclusions 
Increased HIV acquisition among women with higher baseline concentrations of several pro-
inflammatory cytokines suggests local innate immune inflammation may be a mechanism of 
increased risk of HIV acquisition. Understanding the association between innate immunity and 
HIV acquisition is important for the rationale design of biomedical technologies – including both 
microbicides and vaccines – for HIV prevention. 
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INTRODUCTION 
 Many biological risk factors for HIV acquisition, including mucosal epithelial disruption, 
the availability of CCR5+/CD4+ target cells, sexually transmitted infections, disturbances in the 
vaginal microbiota, such as bacterial vaginosis (BV), are well characterized and accepted.[59, 
60]  However, the association between innate immune factors and HIV acquisition remains 
unclear.  Variations in innate immune factor concentrations in the female genital tract have been 
associated with HIV acquisition. In a trial in South Africa, women with increased MIP-1α, MIP-
1β, IP-10 and IL-8 concentrations experienced higher rates of HIV acquisition; this finding was 
also observed within the active trial arm (tenofovir gel) suggesting that local inflammation may 
reduce the effectiveness of tenofovir gel for HIV prevention.[53] Women who seroconverted 
during a multi-center African trial were more likely to have detectable HβD-2 concentrations and 
greater E. coli bactericidal activity compared to women who remained HIV negative, and in a 
separate study among women in Zimbabwe and Uganda, higher RANTES concentrations and 
lower SLPI concentrations were associated with HIV seroconversion.[4, 61] 
We evaluated the effect of innate immune concentrations on HIV acquisition using 
stored specimens collected during FEM-PrEP, a randomized trial of Truvada for prevention of 
HIV acquisition among high-risk women. Understanding the association between innate 
immunity and HIV acquisition is important in the rationale design of biomedical technologies for 
HIV prevention, and for both understanding the results of clinical trials of biomedical HIV 
prevention products and their potential impact on the HIV epidemic. 
METHODS 
Ethics statement 
This research was approved by the FHI 360 Protection of Human Subjects Committee 
and the Office of Human Research Ethics at the University of North Carolina at Chapel Hill. Trial 
participants included this analysis provided informed consent during the FEM-PrEP clinical trial 
for future research on stored specimens. 
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Study design and population 
This prospective case-cohort analysis used data from the FEM-PrEP clinical trial, which 
has been described elsewhere.[3] In brief, FEM-PrEP was a randomized, double-blind, placebo-
controlled trial of once-daily tenofovir disproxil fumarate-emtricitabine [TDF/FTC (marketed as 
Truvada); Gilead Sciences, Foster City, CA] designed to assess the effectiveness and safety of 
TDF/FTC as pre-exposure prophylaxis (PrEP) for HIV prevention among high-risk women in 
Africa.   
Selection of the subcohort 
We randomly selected ~15% of enrolled women stratified by site from clinical study sites 
that contributed at least one incident HIV infection during the clinical trial into a sub-cohort 
independent of case status for an analysis of Truvada drug exposure and HIV acquisition. 
However, the Bloemfontein, South Africa site did not store baseline genital specimens from 
participants, which were used to define our exposures, and was therefore excluded from this 
analysis. Women were eligible for selection into the sub-cohort if they were HIV RNA and DNA 
PCR negative at enrollment and completed at least one follow-up visit, yielding a sub-cohort of 
200 women. Among these 200 women, 164 had stored specimens available for exposure 
assessment including 6 cases (Figure 5.1). 
Selection of cases 
All women from the Bondo, Kenya and Pretoria, South Africa sites who were HIV RNA 
and DNA PCR negative at enrollment, completed at least one follow-up visit and became HIV 
infected between enrollment and 60 weeks of follow-up were included as cases, yielding a total 
of 68 incident HIV infections. Among these 68 cases, 47 women had stored specimens 
available for exposure assessment. 
Ascertainment of exposure 
The following immune markers were quantified in stored endocervical specimens: 
macrophage inflammatory protein (MIP)-1α, MIP-1β, interleukin (IL)-6, IL-8, IL-1α, IL-1β, 
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interferon gamma induced-protein (IP)-10, regulated on activation normal T cell expressed and 
secreted (RANTES), granulocyte macrophage colony-stimulating factor (GM-CSF) and 
secretory leukocyte peptidase inhibitor (SLPI).[4, 5, 42]   
Ascertainment of covariates 
 The following covariates were identified using directed acyclic graphs: age, injectable 
contraception use, reproductive tract/sexually transmitted infections (RTI/STI), presence of 
prostate specific antigen (PSA) (marker of recent unprotected sexual exposure) and TDF/FTC 
use.[62, 63] Age was self-reported by participants at baseline. Participants were required to use 
an effective contraceptive method (defined as oral contraceptive pills (OC), injectables [DMPA 
or NET-EN], implant, IUD or have been previously sterilized) to meet trial eligibility criteria; the 
most frequently used contraceptive methods (i.e., OCs, injectables) were provided at the study 
sites.  Contraceptive use was documented at baseline and during follow-up visits; injection 
dates were recorded for injectable methods. RTI/STI, including bacterial vaginosis (BV), 
Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), Trichomonas vaginalis (TV) and 
syphilis and were diagnosed by laboratory testing and treated at baseline (subsequent RTI/STI 
infection was managed via syndromic diagnosis and treatment). Age, contraceptive method and 
RTI/STI were recorded on standard trial case report forms.  Concentrations of tenofovir (TFV) in 
plasma and intracellular tenofovir diphosphate (TVF-DP) in upper layer packed cells were 
analyzed in stored specimens to assess TDF/FTC use.[11]  TFV and TVF-DP concentrations 
were used to create a 5-level adherence variable in consultation with the study pharmacologist, 
and collapsed into three levels for this analysis (i.e., ‘none/low’ [TFV-DP <10,000 
femtomoles/mL and TFV undetectable], ‘good/excellent’ [TFV-DP>100,000 femtomoles/mL and 
TFV>10 ng/mL] and ‘some’ [TFV-DP and/or TFV values in between the two prior specified 
indices]). 
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Ascertainment of incident HIV infection 
HIV testing was conducted every four weeks from trial enrollment through 60 weeks of 
follow-up using a standardized rapid test algorithm; results were recorded on standardized case 
report forms.  Confirmatory testing was done at the Institute of Tropical Medicine in Belgium on 
specimens from women who had positive antibody results. Time to HIV infection was defined as 
the time between enrollment and date of collection of the first specimen which was HIV RNA 
and/or DNA positive. 
Laboratory methods 
Sterile synthetic swabs were collected and eluted in 1000-1200µL phosphate buffered 
saline (PBS) and the volume which remained after NG/CT testing was stored at -70⁰C during 
the FEM-PrEP trial (between May 2009 and November 2010). Cytokine and SLPI testing was 
conducted on these stored aliquots between July 2012 and April 2013. Cytokine concentrations 
were measured using MilliplexTM Human Cytokine kits (Millipore, MA, USA) on a Bio-PlexTM 
Suspension Array Reader (Bio-Rad Laboratories Inc®, CA, USA) according to a written 
standard operating procedure in accordance with manufacturer instructions; specimens were 
pre-filtered by centrifugation using 0.2µm cellulose acetate filters (Sigma-Aldrich, USA) to 
ensure mucus did not interfere with the assay and were tested in duplicate on the same plate. 
Each sample was also tested on a second plate in order to evaluate inter-assay reproducibility. 
SLPI concentrations were measured in duplicate using the Quantikine Human SLPI 
Immunoassay kit  from R&D Systems (Minneapolis, MN) by adapting the manufacturer’s 
instructions for vaginal specimens (1:400 in calibrator diluent RDT). Optical densities were read 
at 450 nm with a second reference filter of 570 nm using a Biotek ELx800 reader (Vermont, 
USA) and KCJunior Software. PSA testing was performed using the Seratec © PSA semiquant 
assay (Seratec Diagnostica, Göttingen, Germany). A volume of 120µL of filtrated swab elute 
was used for testing according to the manufacturer’s instructions with specimens classified as 
negative, low positive or positive.   
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RTI/STI testing was done during the trial; CT/NG testing was done using polymerase 
chain reaction (PCR) on the Roche Cobas Amplicor platform, TV was detected using wet mount 
microscopy and BV visualized using Gram staining and Nugent scoring. TFV and TVF-DP were 
measured in plasma and upper layer packed cells using protein precipitation and LC-MS/MS 
detection using methods that have been described previously.[3, 52] 
Statistical analysis  
Reliability and reproducibility of cytokine and SLPI readings were assessed using 
Spearman’s rank correlation.  Cytokine concentrations were calculated as the mean of duplicate 
samples from the same plate, the mean of duplicate samples from separate plates if one 
observation was undetectable on the plate with duplicate specimens, the observed 
concentration if only 1/3 readings was detectable and the median value between zero and the 
lowest observed standard if all three observations were undetectable. SLPI concentrations were 
calculated as the mean of duplicate readings; if both observations were below the limit of 
detection, the midpoint between zero and the lower limit of detection was imputed, if both 
observations were above the limit of detection, the upper limit of detection was imputed. 
Cytokines and SLPI were analyzed in multivariable models as: 1) continuous variables, 
and 2) a single dichotomous composite variable of inflammation (cytokines) and a separate 
dichotomous variable for SLPI (< or ≥ the median concentration). For the composite variable, an 
intermediate variable was set equal to the number of cytokines ≥ the median concentration 
(range 0-9) per woman. The median of the intermediate variable was defined as the cut point for 
the final composite inflammation variable. Exploratory analyses were done to evaluate the 
influence of exposure coding.  
Missing covariate data was handled as follows: 1) RTI/STI pelvic exam data were used 
to impute missing results based on syndromic management assessment, 2) contraceptive 
method was carried forward from the previous non-missing visit and 3) TDF/FTC use was 
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carried forward from the previous non-missing visit. TDF/FTC use was coded as none/low 
among all women in the placebo arm. 
Bivariable associations between immune factors and HIV acquisition were assessed 
using Wilcoxon-Mann-Whitney tests.  A Cox-proportional hazard model with pseudo-likelihood 
and robust variance was used to model the association between immune marker concentrations 
and risk of HIV infection over time.[49-51]  Age and RTI/STI were fixed at baseline whereas 
contraceptive method and TDF/FTC use were time-varying. Covariates were evaluated as 
potential effect measure modifiers with retention of covariates pre-specified for likelihood ratio 
tests resulting in p<0.20. Potential confounders that resulted in >10% change in the hazard ratio 
through backwards selection were retained in the final model. All analyses were done using 
SAS® software version 9.3 (SAS Institute, Cary, NC).[48] 
RESULTS 
Most women in this study were young; over half were ≤24 years old. Baseline RTI/STI 
laboratory results were available for 97% of women; 3/11 women with missing RTI/STI results 
had pelvic exam data, all of which were normal, and were classified as RTI/STI negative. 
RTI/STI prevalence was high – 14% of women had at least one STI (NG, CT and/or TV) and 
45% of women had BV resulting in 52% of the population having ≥1 RTI/STI at baseline. Due to 
trial eligibility criteria, all women at baseline were using an effective method of contraception, 
with the majority (66%) using injectables (among those 68% DMPA and 32% NET-EN), 26% 
using oral contraceptives and the remaining 8% having been sterilized or using the IUD or 
implant (Table 5.1). Nearly all women (98%) reported continued use of effective contraception 
throughout follow-up, with DMPA being reported during 43%, NET-EN during 20% and other 
methods during 35% of follow-up time. 
As has been reported before, TDF/FTC use was low in the trial and similarly in this case-
cohort population; 50% of follow-up visit intervals among sub-cohort women in the active arm 
were classified as no/low TDF/FTC use, 26% as some use and 24% as good/excellent use.  
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Immune markers were reliably detected in stored endocervical specimens and intra- and inter-
plate correlation between observations was high (intra-plate ρ range 0.89-0.99, inter-plate ρ 
range 0.70-0.99).  
Younger age, TDF/FTC concentrations consistent with none/low (vs. some and 
good/excellent) use and higher IL-1α concentrations were significantly associated with case 
status (Table 5.1).   
In multivariable modeling of innate immune factors as continuous exposure variables, 
none were significantly associated with HIV acquisition defined as p≤0.05 (Table 5.2).  
However, increased IL-1β and RANTES were associated with HIV acquisition among women 
who were PSA positive at baseline. When restricting the analysis population to women in the 
placebo arm only, MIP-1β and IL-8 were also significantly associated with HIV acquisition 
among women who were PSA positive at baseline (data not shown).  No association was 
observed between inflammation and risk of HIV acquisition when modeling the composite 
inflammation variable (Table 5.3). 
Sensitivity analyses were done to explore the influence of variable coding on effect 
estimates (Figures 5.2, 5.3).  Notably, variations of exposure variable coding had varying 
influence – both in estimate directionality and statistical significance - on the primary effect 
estimates (Figures 5.2, 5.3). 
DISCUSSION  
 Use of a case-cohort study design within a completed large HIV prevention trial provided 
the opportunity to assess the association of innate immune factors and HIV acquisition in vivo 
among a large sample of women. The selection of innate immune markers evaluated in this 
study was informed by prior research and the finding of increased HIV acquisition among 
women with higher concentrations of RANTES, IL-1β, MIP-1β and IL-8 is biologically plausible. 
RANTES has both protective and inflammatory functions in HIV infection, by binding the CCR5 
HIV co-receptor while also functioning as a chemoattractant for target CD4+ T cells. Higher 
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RANTES concentrations have been shown to correlate with increased numbers of HIV-1 targets 
cells in the genital mucosa.[64]  A recent study among women in Uganda and Zimbabwe 
similarly found higher RANTES to be associated with HIV acquisition.[4]  IL-1β is one of two 
members of the IL-1 cytokine family which activates the NF-kβ pathway resulting in activation of 
numerous pro-inflammatory cytokines and increases in IL-1β have been associated as a 
potential mechanism of increased HIV risk observed in women with BV.[65, 66] Both MIP-1β 
and IL-8 are chemoattractant of CCR5+ CD4+ T cells and other cell types (i.e., dendritic cells, 
macrophages) susceptible to HIV infection, respectively.[64, 67] Elevated levels of MIP-1β and 
IL-8 were associated with increased HIV acquisition among women in South Africa.[53] We did 
not observe an association between concentrations of SLPI and IP-10 and HIV acquisition 
which has been observed in other studies.[4, 53] This may be due to insufficient power in our 
study or due to different immune factor measurement methods across studies.  
 The consistent restriction of significant findings to women who were PSA positive at 
baseline may be explained by PSA positivity as an indicator of future HIV exposure. Women 
who were PSA positive had recent unprotected sexual exposure and may represent a 
population of women more likely to have had unprotected sexual exposure, a requirement for 
HIV acquisition, during the trial.  
The influence of exposure coding on point estimates and statistical significance is an 
important finding. Most published research in the area of innate immunity and HIV risk report 
results from analyses using a single exposure classification scheme and there is inconsistency 
in classification schemes across studies which limits comparability of results. Establishment of a 
minimal set of standard exposure classification criteria would be useful for advancing our 
understanding of female innate immunity and HIV acquisition. 
While an original 15% (n=300) subcohort was selected for multiple exposure-outcome 
assessments using FEM-PrEP trial data, genital specimens were only available for 164 women 
from the selected cohort for this analysis, yielding an 8% person-sample (11% person-year 
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sample) from the original cohort. It is possible that the study was underpowered to detect any 
true effects that were not significant in this study. In addition, exposure misclassification may 
have occurred. Genital specimens were only systematically collected at baseline in the parent 
trial.  While one study has suggested intra-person stability of relative cytokine concentrations 
over time, the results must be confirmed.[68] 
In summary, we found that baseline inflammation of several pro-inflammatory cytokines 
was associated with HIV acquisition among women in the FEM-PrEP trial. These data combined 
with the results of other recent clinical studies suggest increased innate immune activity may 
increase women’s risk of HIV acquisition independent of other known risk factors.   
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Tables and Figures 
Figure 5.1 Flow diagram of participant selection 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A randomly selected sub‐cohort of 
participants (stratified by site) 
(n=200, 9 of which are cases) 
Women who became HIV infected 
during regular follow‐up 
(n=68) 
Participants with endocervical 
swab specimens available for 
testing 
(n=47) 
Participants from four study sites 
participating in the FEM‐PrEP 
clinical trial 
(n=2120) 
Eligible cohort 
(HIV RNA and DNA PCR negative at 
enrollment, made one post‐
enrollment study visit, from Bondo 
or Pretoria site) 
(n=720 in Bondo, 750 in Pretoria) 
Cases Sub‐cohort
Participants with endocervical 
swab specimens available for 
testing 
(n=164, 6 of which are cases) 
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Table 5.1 Characteristics of cases and non-cases 
Characteristic 
Cases 
(n=47) 
Non-cases 
(n=158) p† 
Full FEM-
PrEP 
cohort‡ 
(n=2120) 
Total 47 (23) 158 (77) ---  
 Bondo, Kenya, n (%) 24 (22) 87 (78) 0.62 739 (35)  Pretoria, South Africa, n (%) 23 (24) 71 (76) 764 (36) 
Age, median (range) 23 (18-33) 
25 
(18-35) 0.03 
23 
(18-35) 
Contraceptive method at baseline, n (%)     
 Oral contraceptive pills 16 (34) 38 (24) 0.17 638 (30) 
 
Depot medroxyprogesterone acetate 
(DMPA) 20 (43) 72 (46) 0.72 820 (39) 
 Norethisterone enanthate (NET-EN) 10 (21) 34 (22) 0.97 581 (27) 
 Female sterilization 1 (2) 5 (3) 1.00 39 (2) 
 Implant 0 (0) 8 (5) 0.20 34 (2) 
 IUD 0 (0) 1 (1) 1.00 8 (<1) 
Contraceptive method during follow-up, n (%) ᵟ     
 
Depot medroxyprogesterone acetate 
(DMPA) 130 (44) 758 (44) 0.66 N/A 
 Norethisterone enanthate (NET-EN) 52 (18) 341 (20) 0.32 N/A 
 Other or none 114 (39) 625 (36) Ref N/A 
Reproductive tract infections at baseline, n (%)      
 Chlamydia 6 (13) 11 (7) 0.23 108/1887 (6) 
 Gonorrhea 4 (9) 4 (3) 0.08 
264/1887 
(14) 
 Trichomoniasis 2 (4) 3 (2) 0.33 109/1893 (6) 
 Syphilis 2 (4) 4 (3) 0.62 36/2118 (2) 
 Bacterial vaginosis ᶲ 26 (58) 67 (45) 0.13 
785/1877 
(42) 
 ≥1 STI and/or BV κ 28 (61) 74 (50) 0.18 999 (47) 
Truvada adherence during follow-up ᵟ,^     
 None/low 67 (39) 449 (52) Ref NA 
 Some 59 (34) 210 (24) <0.01 NA 
 Good/excellent 46 (27) 203 (24) 0.05 NA 
Cytokine concentration, median (pg/mL)     
 MIP-1α 13.3 11.6 0.94 NA 
 MIP-1β 17.3 18.9 0.93 NA 
 IL-6 12.3 8.7 0.52 NA 
 IL-8 475.6 385.5 0.33 NA 
 IP-10 37.7 26.4 0.31 NA 
 IL-1α 93.7 52.0 0.02 NA 
 IL-1β 8.2 4.9 0.08 NA 
 RANTES 3.9 2.6 0.39 NA 
 GMCSF 1.6 1.6 0.84 NA 
SLPI (pg/mL) 951.3 1033.4 0.68 NA 
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Person-years of follow-up (total) 159 --- 1407 
† P values for the difference between cases and non-cases; Wilcoxon Mann Whitney (for non-normally 
distributed continuous variables) or chi-square test/Fisher’s exact for categorical variables. 
‡ NA = data not available for full cohort 
ᵟ n=number of follow-up visit intervals 
^ active arm participants only 
ᶲ Bacterial vaginosis defined as Nugent Score 7-10 
κ Defined as ≥ 1 of CT, NG, TV and BV 
 
 Figure 5.2 Influence of variable (continuous) coding on hazard ratios 
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Figure 5.3 Influence of variable (composite) coding on hazard ratios 
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Table 5.2 Risk of HIV acquisition by baseline genital immune marker concentrations 
(continuous) 
 Bivariable analysis Multivariable analysis‡ 
 HR (95% CI)† P HR (95% CI)† P 
MIP-1α1 0.37 (0.08, 1.76) 0.21 --- --- 
None/low adherence --- --- 0.84 (0.56, 1.27) 
0.40 Some adherence --- --- 0.01 (0.00, 2.81) 
Good/excellent adherence --- --- 0.27 (0.01, 12.05) 
MIP-1β2 0.37 (0.02, 7.65) 0.52 --- --- 
Negative RTI/STI --- --- 0.11 (0.01, 1.63) 
0.11 
Positive RTI/STI --- --- 4.82 (0.06, 424.01) 
IL-63 0.81 (0.56, 1.15) 0.23 --- --- 
IL-83 1.02 (0.85, 1.22) 0.87 --- --- 
Negative PSA --- --- 0.83 (0.63, 1.08) 
0.17 
Positive PSA --- --- 1.38 (0.98, 2.00) 
IL-1α4 0.98 (0.83, 1.16) 0.82   
None/low adherence --- --- 0.88 (0.71, 1.09) 
0.24 Some adherence --- --- 1.52 (0.93, 2.49) 
Good/excellent adherence --- --- 1.04 (0.16, 6.89) 
IL-1β3 1.03 (0.86, 1.25) 0.75   
Negative PSA, ≤ 23 years --- --- 0.34 (0.05, 2.52) 
0.39 
Negative PSA, >23 years --- --- 0.50 (0.10, 2.45) 
Positive PSA, ≤ 23 years --- --- 75.06 (25.64, 219.76) 
Positive PSA, >23 years --- --- 111.06 (3.99, 3090.70) 
IP-105 0.96 (0.75, 1.23) 0.75 --- --- 
None/low adherence --- --- 1.00 (0.81. 1.24) 
1.00 Some adherence --- --- 0.06 (0.01, 0.65) 
Good/excellent adherence --- --- 1.20 (0.67, 2.15) 
RANTES3 1.34 (0.74, 2.41) 0.33 --- --- 
Negative PSA, negative RTI/STI --- --- 0.61 (0.18, 2.00) 
0.41 
Negative PSA, positive RTI/STI --- --- 1.32 (0.54, 3.22) 
Positive PSA, negative RTI/STI --- --- 0.84 (0.26, 2.74) 
Positive PSA, positive RTI/STI --- --- 1.84 (1.55, 2.19) 
GMCSF6 0.94 (0.73, 1.20) 0.60 0.90 (0.70, 1.16) 0.46 
SLPI3 1.00 (0.89, 1.13) 0.95 --- --- 
†HRs per 20% increase in concentration 
‡ HRs presented by level of interaction term where interaction term likelihood ratio test p<0.20 
^ Positive NG, CT, TV and/or BV results 
1 Model controlling for baseline RTI/STI, use of injectable contraception and age 
2 Model controlling for age 
3 No covariates retained in model 
4  Model controlling for use of injectable contraception and age 
5  Model controlling for use of injectable contraception 
6  Model controlling for baseline RTI/STI 
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Table 5.3 Risk of HIV acquisition by baseline genital immune marker concentrations (composite) 
 Bivariable analysis Multivariable analysis‡ 
 HR (95% CI)† P HR (95% CI)† P 
Inflammation^   0.92        (0.49, 1.72) 0.76 --- --- 
Truvada use (no/low) --- --- 1.25 (0.57, 2.76) 
 
0.58 Truvada use (some) --- --- 
0.32 
(0.05, 1.92) 
Truvada use (good/excellent) --- --- 1.89 (0.16, 21.87) 
SLPI 1.00 (0.89, 1.13) 0.95 1.037 (0.92, 1.17) 0.57 
†HRs per 20% increase in concentration 
‡ HRs presented by level of interaction term where interaction term likelihood ratio test p<0.20.  Model 
controlling for baseline RTI/STI and age. 
^ Inflammation classified as ≥ 5 inflammatory cytokines (MIP-1α, MIP-1β, IL-8, IP-10, IL-1α, RANTES, IL-6, 
IL-1β, GMCSF) above the median concentration 
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CHAPTER 6: DISCUSSION 
Aim 1: Cross sectional analysis of the association between selected immune biomarkers, 
injectable progestin-only contraception and RTIs 
 
Summary of Findings 
 No significant variability in marker concentrations was observed by age or site. DMPA 
users had significantly higher MIP-1α, MIP-1β, IL-6, IL-8, IP-10 and RANTES concentrations. 
NET-EN users had significantly higher IL-6, IL-8 and RANTES concentrations. Women with 
STIs had variable inflammation, and women with BV exhibited a mixed phenotype of up and 
downregulation. 
Interpretation 
 A similar marker profile in DMPA and NET-EN users suggest IPC may induce changes 
in the innate immune environment of the female genital tract. Numerous immunologic studies 
have shown RANTES to be both an effective blocker of the HIV CCR5 co-receptor, yet a potent 
chemoattractant of CD4+ T cells, the primary cell target of HIV. The consistent finding of 
RANTES elevation among DMPA users in this analysis and in that of Morrison et. al., combined 
with the aforementioned immunological evidence, suggests RANTES elevation as a potential 
mechanism of the increased rate of HIV acquisition among DMPA users observed in 
epidemiological studies. Women using DMPA and NET-EN did not have any significant 
decrease in SLPI levels suggesting that the potential increased risk of HIV infection in IPC users 
is not due to a decrease in this protective protein. However, the innate immune system is 
complex and interactive, and no single marker likely functions in isolation to alter HIV risk. We 
also found DMPA use to be associated with increased MIP-1α, MIP-1βIL-6, IL-8 and IP-10, all of 
which were associated with significantly increased risk of HIV infection in the CAPRISA 004 
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study. The collective results of this, and the aforementioned studies, suggests elevated 
inflammatory cytokine concentrations to be one potential mechanism of the observed increased 
risk of HIV infection among DMPA users. Because NET-EN is rarely used outside of South 
Africa, globally only a small proportion of women using hormonal contraception utilize this 
method. However, within South Africa, which is also the epicenter of the HIV epidemic, NET-EN 
is widely used. The similar profile of elevated cytokines in DMPA and NET-EN users suggests 
that further research is needed to more broadly clarify any potential association between IPC 
and HIV risk. Lastly, data from several other studies demonstrates a potential modification of the 
effects of exogenous hormones on the innate immune environment, and inversely, a 
modification of RTI risk in the presence of exogenous hormone use. While the magnitude of 
these effects is unclear, our data suggest that IPC use and RTIs are also both independently 
associated with changes to the innate immune environment. 
Limitations 
 Due to the cross-sectional nature of our study design, causality of any of the exposures 
on the measured immune markers cannot be established. However, the strict inclusion criteria 
and participant sampling approach utilized, along with measurement of PSA to control for recent 
sexual activity, methodologically controls for many potential confounders including pregnancy, 
comorbid RTIs and HIV. The lack of complete HSV-2 data among women in this study may 
have affected the results. However, a recent paper by Masson et al which sought to 
characterize innate immune profiles of women with STIs found no association between HSV-2 
status as measured by antibody detection in serum or active infection with viral 
shedding.[55]Similarly, the lack of available data on infections with other pathogens (e.g., 
human papillomavirus, Mycoplasma genitalium) may have affected our results. We were only 
able to measure a selection of cytokines and SLPI, and do not have data on other markers of 
the local immune response such as total lymphocytes, markers of cellular activation, 
immunoglobulins and other proteins that may be of relevance (e.g., IFN-α, IFN-β, IFN-γ, IL-1R, 
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IL-1Ra, human α- and β-defensins), though the panel of selected cytokines was informed by the 
results of previous studies.[2, 4, 14, 16, 69-73]  Although cytokines are important biomarkers of 
immune processes in the female genital tract, particularly inflammation, different results 
between studies emphasize the need for the development of standardized approaches to 
marker selection, testing methods, specimen collection methods and storage conditions and 
confounder data collection to allow for better comparability of results across studies. 
Future research directions 
 A longitudinal study is needed to better determine if the observed associations with IPC 
use are causal in nature. We are currently preparing a research proposal that will utilize 
stringent laboratory and behavioral baseline evaluations, inclusion criteria and visit timing (in 
regard to hormonal cycling) to better study the effects of HC use on the innate immune 
environment.  
 
Aim 2: Case-cohort analysis of innate immune inflammation as a risk factor for HIV 
acquisition 
 
Summary of Findings 
 In bivariate analysis, younger age, FTC/TDF concentrations consistent with no/low (vs. 
some and good/excellent) use and higher IL-1α concentrations were significantly associated 
with incident HIV infection. In multivariate modeling using the single cytokine inflammation 
variable, none of the selected immune markers were significantly associated with risk of HIV 
infection. Injectable contraceptive use was removed from the final model according to previously 
defined criteria; adherence to FTC/TDF was retained as an interaction term. Younger women 
(<23 years old) had lower risk of HIV infection as compared to older women (≥23 years old) 
(despite a marginal p-value (0.07), age exerted a substantial influence on the primary exposure 
effect estimates and was retained in the final model). Women with baseline STI and/or BV had a 
74% greater risk of infection than women with no STI/BV at baseline (again, result was not 
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significant at p≤0.05 but variable had a substantial influence on effect estimates and was 
retained). When modeling using ten dichotomous exposure variables (i.e., < vs. ≥ median), IP-
10 was significantly associated with risk of HIV infection as was baseline STI/BV. Age remained 
marginally significant. However, when modeling using continuous exposure variables, RANTES 
was significantly associated with risk of HIV infection. 
Interpretation and Public Health Significance 
 The overall lack of observed association between the selected markers and HIV 
acquisition may be attributable to study design limitations. The association between age and 
baseline STI/BV infection and HIV risk, and the overall prevalence of STI/BV in this cohort, are 
notable. Young women remain at unacceptably high risk of HIV infection, and both age and 
prevalent RTI/STI may be effective tools for identifying those who would benefit most from 
targeted HIV prevention efforts. The field of innate immunity and HIV risk is in need of 
standardized methods for measuring and analyzing immune markers. 
The association between younger age and increased risk of HIV infection has been 
repeatedly observed among young women in sub-Saharan Africa, and has been reported from 
the parent FEM-PrEP trial.[8, 74-76] More recent data from a large prevention trial suggest that 
this risk has not declined in recent years and that young women remain at unacceptably high 
risk.[12] Moreover, the finding of substantial RTI prevalence at baseline reveals a substantial 
burden of treatable disease in this population. Notably all women with an RTI diagnosis received 
treatment during the trial; therefore, the observed increased risk among these women was 
unlikely due to any biological effect of the baseline RTI, but rather subsequent risk behavior, 
which may have included repeat infection. This finding suggests that prevalent RTI may be used 
as an indicator of future HIV risk. Currently, most public health programs in sub-Saharan Africa 
rely on syndromic diagnosis, which has been documented to substantially underestimate 
infection. Use of more sensitive RTI screening tools could potentially reduce HIV incidence by 
multiple mechanisms, both through effective identification and treatment of active STIs which 
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likely increase the biological risk of HIV infection, as well as through identification of individuals 
who may be at increased risk of future HIV exposure and infection for targeted prevention 
intervention. 
Limitations 
 While an original 15% (n=300) subcohort was selected for multiple exposure-outcome 
assessments using FEM-PrEP trial data, genital specimens were only available for 164 women 
from the selected cohort for this analysis, yielding an 8% person-sample (11% person-year 
sample) from the original cohort. It is possible that the study was underpowered to detect any 
true effects that were not observed. In addition, exposure misclassification may have occurred. 
Genital specimens were only systematically collected at baseline in the parent trial.  While one 
study has suggested intra-person stability of relative cytokine concentrations over time, that 
study was also limited by small sample size; the true nature of cytokine stability over time 
remains unclear and further research is necessary for meaningful use of these markers in 
analyses of HIV acquisition. 
Future research directions 
All studies conducted in vivo in women on the subject of innate immune factors and HIV 
risk have been conducted as secondary analyses of studies not designed to answer the 
research questions. The limitations of this approach include distant timing between marker 
measurement and study endpoints (i.e., HIV infection or censoring) and inadequate collection 
of, or delineation of, potentially important confounder data. While studies with HIV infection 
endpoints are costly and a study designed to look at immune factors and incident HIV infection 
would not likely be funded, a sub-study designed to answer these questions adjoined to a larger 
HIV study would be a viable and cost-effective method to more definitively address these 
questions. In addition, data in this area are not sufficiently robust (in terms of sample size and 
control of covariates that influence markers) to as yet define the optimal coding scheme, and as 
such, there is substantial inconsistency in classification schemes across studies which limits 
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comparability of results. Establishment of a minimal set of exposure measurement classification 
criteria would be useful for advancing our understanding of female innate immunity and HIV 
acquisition. In the interim, researchers should evaluate the influence of coding schemes on 
effect estimates in sensitivity analyses of their results. 
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APPENDIX 1: STANDARD OPERATING PROCEDURE: HUMAN CYTOKINE MAGNETIC 
BEAD PLATE ASSAY 
 
1 General information 
 
1.1 Aim and application 
 
The test is used to simultaneously detect multiple selected cytokines in vaginal biological 
samples. 
 
1.2 Principle 
 
MILLIPLEX MAP is based on the Luminex® xMAP® technology which is capable of 
performing a variety of bioassays including immunoassays on the surface of fluorescent-
coded magnetic beads known as MagPlex TM-C microspheres. 
 
 Luminex uses proprietary techniques to internally color-code microspheres with two 
fluorescent dyes. Through precise concentrations of two dyes, 100 distinctly colored 
bead sets can be created, each of which is coated with a specific capture antibody. 
 After an analyte from a test sample is captured by the bead, a biotinylated detection 
 antibody is introduced. The reaction mixture is then incubated with Streptavidin PE 
conjugate, the reporter molecule, to complete the reaction on the surface of each 
microsphere. 
 The microspheres are allowed to pass rapidly through a laser, which excites the 
internal dyes marking the microsphere set. A second laser excites PE, the 
fluorescent dye on the reporter molecule. 
 Finally, high-speed digital-signal processors identify each individual microsphere and 
quantify the result of its bioassay, based on fluorescent reporter signals. 
 
The capability of adding multiple conjugated beads to each sample results in the ability to 
obtain multiple results from each sample. Open-architecture xMAP technology enables 
multiplexing of many types of bioassays reducing time, labor and costs over traditional 
methods. 
 
1.3 Reagents required not provided in kit 
 Diluted Phosphate buffered saline (PBS; # 8582680) 
 Weighing 0.96 g PBS and 7.65g NaCl. 
 Dissolve in 1L MBW. 
 Sterilize by filtration. 
 Store at 2 - 8°C. 
 Bleach (10%) 
 Isopropanol (70%) 
 BioRad Bio-Plex Validation Kit (catalogue # 171-203001) 
 BioRad Bio-Plex Calibration Beads set (catalogue # 171-203060 
 BioRad Bio-Plex Sheath Fluid (catalogue # 171-000055) 
 
1.4 Apparatus, equipment and materials 
 Micro-pipettes (200;1000 l) 
 Multichannel pipettes (50; 300 µl)  
 Filter tips (200;1000 l) 
 Spin-X Centrifuge Filter Tube 
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 Plate sealers 
 Duran Bottle 1L 
 Biological safety cabinet Class II 
 Refrigerator (2-8°C) 
 Freezer (-80°C ± 5°C) 
 Disposable Gloves 
 Lab Coats + sleeve protectors 
 Racks for cryotubes 
 Vortex 
 Eppendorf tubes, 1.5ml conical 
 Falcon tubes (50 ml) 
 Reagent reservoirs 
 Aluminum foil 
 Absorbent pads or paper towels 
 Waste receptacle 
 Plate shaker 
 BioRad Bio-Plex 200 System and Bio-Plex Manager Software 
 Hand held magnetic block 
 
1.5 Samples for analysis 
 Vaginal secretions collected by using dry synthetic swabs eluted in diluted PBS and 
stored at -80°C ± 5°C. 
 
 RAYON® Swabs 
 Thaw the swabs samples overnight at 2-8°C on ice. 
 Determine the correct number of 2.0 ml screw-cap Sarstedt tubes needed. Label 
two tubes and one Spin-X filter tube for each patient sample and place in rack. 
 Pipette 1.2 ml PBS buffer directly onto the swab inside its cover using a sterile 
disposable pipette. 
 Vortex for 15 sec. 
 Remove the diluted PBS again with the disposable pipette and transfer it into the 
Eppendorf tube. 
 Pipette 750 μl sample over into Spin-X filter tube and close the cap.  
 Centrifuge the Spin-X filter tube at maximum speed for 10 min in a 
microcentrifuge. 
 Load the remaining volume of the samples on the corresponding Spin-X filter and 
centrifuge at maximum speed for 10 min. 
 Take out the filter from the Spin-X filter tube and discard. 
 Pipette 100 µl of the sample in the second labeled Eppendorf tube.  
 Store both samples tubes (Spin-X tube and the Eppendorf tube) at -80°C. 
  
3 Definitions and abbreviations 
 PBS : Phosphate buffered saline 
 NaCl : Sodium Chloride 
 MBW : Molecular Biology grade Water 
 BVK : Biological safety cabinet 
 MLT : medical laboratory technologist 
 SOP : Standard Operating Procedure 
 MFI : Median Fluorescent Intensity  
 5PL : 5-parameter logistic 
 Std : standard 
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4 Method 
 
4.1 Sample Preparation 
 
Preparation of endocervical swab PBS eluted samples: 
 Thaw samples on ice in an icebox at 2-8°C. 
 Samples to be kept on ice during processing. 
 In a BVK, vortex samples and transfer a maximum of 750 µl to a labeled Corning 
Spin-X Centrifuge Filter tube. 
 Centrifuge at 13,000 rpm for 10 minutes. 
 Transfer 100 µl aliquots to separate, labeled sterile Eppendorf tube and retain 
remaining volume in Spin-X Centrifuge filter tube (filter is discarded). 
 Store at -80°C ± 5°C. 
 Avoid multiple (>2) freeze/thaw cycles. 
 
4.2 Kit Storage Conditions 
 
 Recommended storage for kit components is 2-8°C. 
 Once the standards and controls have been reconstituted, immediately transfer 
contents into polypropylene vials. DO NOT STORE RECONSITUTED STANDARDS 
OR CONTROLS IN GLASS VIALS. For long-term storage, freeze reconstituted 
standards and controls at ≤-20°C. Avoid multiple (>2) freeze thaw cycles.  
 DO NOT FREEZE Antibody-Immobilized Beads, Detection Antibody, and 
Streptavidin-Phycoerythrin. 
 
4.3 Technical Guidelines  
 
To obtain reliable and reproducible results, the operator should carefully read the entire kit 
protocol and this SOP and fully understand all aspects of each assay step before running the 
assay. The following notes should be reviewed and understood before the assay is set-up. 
 
 FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES. 
 Do not use beyond the expiration date on the label. 
 Do not mix or substitute reagents with those from other lots or sources. 
 The Antibody-Immobilized Beads are light sensitive and must be protected from light 
at all times. Cover the assay plate containing beads with opaque plate lid or 
 aluminum foil during all incubation steps. 
 It is important to allow all reagents to warm to room temperature (20-25°C) before 
use in the assay. 
 Incomplete washing can adversely affect the assay outcome. All washing must be 
performed with the Wash Buffer provided. 
 After hydration, all standards and controls must be transferred to polypropylene 
tubes. 
 The standards prepared by serial dilution must be used within 1 hour of preparation. 
 Discard any unused standards except the standard stock which may be stored at ≤ -
20°C for 1 month and at ≤ -80°C for greater than one month. 
 If samples fall outside the dynamic range of the assay, further dilute the samples with 
the appropriate diluent and repeat the assay. 
 Any unused mixed Antibody-Immobilized Beads may be stored in the Bead Mix 
bottle at 2-8°C for up to one month. 
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 During the preparation of the standard curve, make certain to mix the higher 
concentration well before making the next dilution. Use a new tip with each dilution. 
 The plate should be read immediately after the assay is finished. If, however, the 
plate cannot be read immediately, seal the plate, cover with aluminum foil or an 
opaque lid, and store the plate at 2-8°C for up to 24 hours. Prior to reading, agitate 
the plate on the plate shaker at room temperature for 10 minutes. Delay in reading a 
plate may result in decreased sensitivity for some analytes. 
 The titer plate shaker should be set at a speed to provide maximum orbital mixing 
without splashing of liquid outside the wells. For the recommended plate shaker, this 
would be a setting of 5-7, which is approximately 500-800 rpm. 
 Ensure that the needle probe is clean. This may be achieved by sonication and/or 
alcohol flushes. 
 Vortex all reagents well before adding to plate. 
 
4.4 Preparation of reagents: 
 
A. Preparation of Individual Vials of Beads.   
 For individual vials of beads, vortex each antibody-bead vial for 2 minutes. 
 If vortexing 2-3 vials of beads simultaneously, vortex each individual vial for a 
few seconds just before addition of beads to the Mixing Bottle. 
 
 Add 60 μL from each of the 9 antibody bead vials to the Mixing Bottle and bring final 
volume to 3.0 mL with Bead Diluent by adding 2,460 µL bead diluent.  
 
List of beads used for testing: 
 
Beads  
44_Anti Human IL-1α Bead 74_Anti-Human RANTES Bead 
63_Anti-Human IL-8 Bead 46_Anti-Human IL-1β Bead 
65_Anti-Human IP-10 Bead 57_Anti-Human IL-6 Bead 
72_Anti-Human MIP-1α 
Bead 20_Anti-Human GM-CSF Bead 
73_Anti-Human MIP-1β 
Bead  
  
B. Preparation of Quality Controls 
 Before use, reconstitute Quality Control 1 and Quality Control 2 with 250 μL deionized 
water.  
 Invert the vial several times to mix and vortex.  
 Allow the vial to sit for 5-10 minutes and then transfer the controls to appropriately 
labeled polypropylene microfuge tubes.  
 
Unused portion may be stored at -20°C for up to one month. 
 
C. Preparation of Wash Buffer 
 Bring the 10X Wash Buffer to room temperature and mix to bring all salts into 
solution.  
 Dilute 30 mL of 10X Wash Buffer with 270 mL deionized water.  
 
Store unused portion at 2-8°C for up to one month. 
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D. Preparation of Human Cytokine Standard 
 Prior to use, reconstitute the Human Cytokine Standard with 250μL deionized water 
to give a 10,000 pg/mL concentration of standard for all analytes.  
 Invert the vial several times to mix.  
 Vortex the vial for 10 seconds.  
 Allow the vial to sit for 5-10 minutes and then transfer the standard to an appropriately 
labeled polypropylene microfuge tube.  
 
 This will be used as the 10,000 pg/mL standard; the unused portion may be 
stored at  -20°C ± 5°C for up to one month. 
 
 Label five polypropylene microfuge tubes 2,000, 400, 80, 16, and 3.2 pg/mL.  
 Add 200 μL of Assay Buffer to each of the five tubes.  
 Prepare serial dilutions by adding 50 μL of the 10,000 pg/mL reconstituted 
standard to the 2,000 pg/mL tube,  
 mix well and transfer 50 μL of the 2,000 pg/mL standard to the 400 pg/mL tube,  
 mix well and transfer 50 μL of the 400 pg/mL standard to the 80 pg/mL tube, 
 mix well and transfer 50 μL of the 80 pg/mL standard to 16 pg/mL tube,  
 mix well and transfer 50μL of the 16 pg/mL standard to the 3.2 pg/mL tube and 
mix well.  
 The 0 pg/mL standard (Background) will be Assay Buffer.  
 
  Scheme: 
 
 
4.5 Immunoassay Procedure  
 
Prior to beginning this assay, it is imperative to read this SOP completely and to thoroughly 
understand the Technical Guidelines.  
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 Allow all reagents to warm to room temperature (20-25°C) before use in the assay.  
 Diagram the placement of Standards [0 (Background), 3.2, 16, 80, 400, 2,000, and 
10,000 pg/mL], Controls 1 and 2, and samples on Well Map Worksheet in a vertical 
configuration.  
 It is recommended to run the assay in duplicate.  
 
 Thaw the testing samples OVERNIGHT at 2-8°C on ice. 
 Fill a non-testing plate with the samples by adding 100 µl of each sample into the 
appropriate wells of the empty microtiter plate. Seal the plate with a plate sealer and 
store in the refrigerator at 2-8°C until transfer of the samples into the cytokine testing 
plate.  
 Start the following preparations: 
 Preparation of Individual Vials of Beads (see instructions above).   
 Preparation of Quality Controls (see instructions above). 
 Preparation of Wash Buffer (see instructions above). 
 Preparation of Human Cytokine Standard (see instructions above). 
 
 Add 200 μL of Wash Buffer into each well of the cytokine testing plate (plate from the 
kit). Seal and mix on a plate shaker for 10 minutes at room temperature (20-25°C).  
 Decant Wash Buffer and remove the residual amount from all wells by inverting the 
plate and tapping it smartly onto absorbent towels several times. 
 Add 25 μL of Assay Buffer to the sample wells of the cytokine testing plate.  
 Add 25 μL of diluted PBS to the background, standards, and control wells of the 
cytokine testing plate. Seal the plate with a plate sealer.. 
 Bring out the non-testing plate from the refrigerator.  
 Add 100 µL of each Standard or Control into the appropriate wells of the non-testing 
plate. Assay Buffer should be used for 0 pg/mL standard (Background). 
 Using a multichannel, transfer 25 µl of the samples from the non-testing plate into the 
cytokine testing according to the worksheets. 
 Mix the samples thoroughly by aspirating up and down with the pipette 5 times. 
 Vortex the Mixing Bottle for 2 minutes and then add 25 μL of the Mixed Beads to each 
well of the cytokine testing plate.  
 
 During addition of Beads, tilt trough containing beads periodically while adding to 
wells to prevent settling of beads.  Beads are light sensitive, turn off lights as 
possible.)  
 Once beads are added to the plate wells the plate must be protected from light as 
much as possible. 
 
 Seal the plate with a plate sealer. Wrap the plate with foil and incubate with agitation 
(600 rpm) on a plate shaker for 16 hours at 2-8°C (cold room).  
 
 An overnight incubation may improve assay sensitivity for some analytes.  
 
 Unwrap the plate from foil and wash plate  following instructions listed below:  
 
 Rest plate on hand-held magnet for 60 seconds to allow complete settling of 
magnetic beads. Cover plate with aluminum foil during settling of beads. 
 Plate remains attached on the hand-held magnet: remove foil and sealer from 
the plate.  
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 Remove well contents by gently decanting the plate in a waste receptacle. 
 Gently tap on absorbent pads to remove residual liquid.  
 Remove plate from the hand-held magnet. 
 Add 200 µL of Wash Buffer to each well. 
 Seal, cover with foil and incubate with agitation on a plate shaker at 600 rpm for 
30 seconds at room temperature (20-25°C). 
 Reattach plate to the hand-held magnet for 60 seconds and repeat wash step  
once. 
 
 Add 25 μL of Detection Antibodies into each well. (Note: Allow the Detection Antibodies 
to warm to room temperature prior to addition.) 
 Seal, cover with foil and incubate with agitation on a plate shaker for 1 hour at room 
temperature (20-25°C). DO NOT ASPIRATE AFTER INCUBATION. 
 Add 25 μL Streptavidin-Phycoerythrin to each well containing the 25 μL of Detection 
Antibodies. 
 Seal, cover with foil and incubate with agitation on a plate shaker for 30 minutes at room 
temperature (20-25°C). 
 Unwrap the plate from foil and wash plate following instructions listed below: 
 
 Rest plate on hand-held magnet for 60 seconds to allow complete settling of 
magnetic beads. Cover plate with aluminum foil during settling of beads. 
 Plate remains attached on the hand-held magnet: remove foil and sealer from 
the plate.  
 Remove well contents by gently decanting the plate in a waste receptacle. 
 Gently tap on absorbent pads to remove residual liquid.  
 Remove plate from the hand-held magnet. 
 Add 200 µL of Wash Buffer to each well. 
 Seal, cover with foil and incubate with agitation on a plate shaker at 600 rpm for 
30 seconds at room temperature (20-25°C). 
 Reattach plate to the hand-held magnet for 60 seconds and repeat wash step 
once. 
 
 Add 150 μL of Sheath Fluid (or Drive Fluid if using MAGPIX®) to all wells. Resuspend the 
beads on a plate shaker for 10 minutes.  
 IF plate cannot be processed immediately, no Sheath Fluid is added. Store plate 
sealed and wrapped in aluminum foil at 2-8°C.  
 Resuspend the beads on a plate shaker for 10 minutes before running the plate 
on the Bioplex array reader.    
 
 Run plate on Bio-Plex 200 system. 
 Save and analyze the Median Fluorescent Intensity (MFI) data using a 5-parameter 
logistic (5PL) method for calculating cytokine/chemokines concentrations in samples.  
 
4.6 Bio-Plex 200 System start up 
 
Machine may be started up while plate is on shaker after adding the Detection Antibodies to 
the wells. Start up takes approximately 10 minutes. 
 
1. Empty waste bottle. Recap the bottle and close firmly. 
2. Fill sheath fluid bottle to fill line if needed. Recap the bottle and close firmly. 
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3. Turn on Bio-Plex 200 system via the two switches at the backside of the instrument. 
Switch on the PC. 
4. Login to computer and start software. Click “Start Up” and follow on screen 
instructions; by filling the 70% isopropanol and deionized water reservoirs to run the 
start up procedure.  Eject plate holder, insert calibration plate and click “OK”. 
5. While start up runs, open a new experiment by clicking top left blank template icon. 
 Select “2. Select Analytes” and choose all analytes to be analyzed. Confirm the 
regions for each analyte using the bead bottles (see list of beads to be tested 
above_open file: FEM-PrEP HCYTOMAG with Rantes). 
 Select “3. Format Plate” and set up plate to match worksheet including blanks, 
standards, controls and samples. 
 Select “4. Enter Standards Info” and enter description and concentrations of 
standards. 
  Ensure “same concentration values for all analytes” box is checked. 
  Ensure regression type is “logistic – 5PL”. 
  Enter “pg/ml” in concentration units field. 
 Not necessary to add any information to “5. Enter Control Info” screen. 
 Select “6. Enter Sample Info” and enter or copy from excel lab numbers of 
samples into description field. Dilution column should all be 1.0. 
 Review the lab numbers to ensure no  transcription errors are present if 
manually entered. 
 Select “7 Run Protocol”: Enter “50” in “Beads per region” field. Click “Advanced 
Settings” and enter “100 µL” in “sample volume” field and click “override gates” 
box. Enter “4500” in low box and “20,000” in high box. Thick: Autosave after run. 
Be sure to save the protocol set-up to the hard drive. 
 
4.6.1 Alternative for programming a new run 
 
1. Select “Open Protocol”: Open a previously programmed template with the 
same testing format. 
2. Select “6: Enter Sample Info” and enter or copy from excel lab numbers of 
samples into description field. Dilution column should all be 1.0. 
  Review the lab numbers to ensure no transcription errors are present. 
3. Select “7 Run Protocol”. Check the following:  
 “50” in “Beads per region” field.   
 Click “Advanced Settings”: “100 µL” in “sample size” field.   
 Click “override gates” box: “4500” in low box and “20,000” in high box 
and then confirm with “Yes”. 
4. Tick “ Rerun/Recovery Mode. 
5. Tick all boxes in the “WELL” field. 
6. Save as new protocol. 
7. Click START to initiate the run. 
  
4.7 Optics Warm Up  
 
To ensure accurate and reproducible results, the optics (i.e., the lasers) in the Bio-Plex 
array reader must warm up for at least 30 minutes prior to calibration and reading 
assays. Optics warm up begins when you first turn on the array reader. 
 
4.8 Calibration 
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Before calibrating, make sure that optics warm up is complete.  
 Remove calibration beads from refrigerator and confirm these are within the 
expiry window. 
 Vortex red and green top calibration beads for 2 minutes. 
 Select “Calibrate” in top right corner and follow on screen instructions. 
  Add 5 drops of each calibration bead to the calibration plate. 
 Add distilled water to the calibration plate. 
 
 The Bio-Plex array reader should be calibrated each day after the start up 
procedure is complete and the optics have warmed up. Also, the array reader 
must be re-calibrated if the instrument temperature changes by more than 2º C 
during the course of the day. The array reader includes a temperature gauge; if 
the temperature changes by more than 2º C, a message box will prompt you to 
recalibrate. 
 
4.9 Plate analysis 
 
 Insert test plate into machine. Remove adhesive plate cover after placing plate in 
holder. 
 Click “start”. Run will take 45-60 minutes. 
 Once the run is complete, evaluate standard curves, quality controls and select 
output data. 
 
4.9.1 Evaluate standard curve 
 Choose red check box icon and select columns for data export including: 
Type, Well, Outlier, Description, Fl, Fl-background, Std Dev, and %CV, 
Obs conc, Observed concentration x 100. 
 Ensure “save settings” is clicked.   
 Click “show replicates” icon (automatic output is average of replicate 
observations).  
 Review “observed concentration x 100” column. The values should be 
close to 100%. (Note: MIP-1α often plateaus).  
 Modify the standard curve calculation by checking “outlier” as needed to 
exclude selected observations from the calculation. Exclude as few 
values as necessary. 
 View standard curve by clicking on “Standard Curve” on left side of 
screen. 
 Repeat steps for each analyte. 
 Save the results file to the hard drive. 
 Eject plate from Bio-Plex 200 system and attach used plate to magnet, 
allow to stand for 60 seconds and dump contents.  Store plate wrapped in 
aluminum foil at 2-8°C overnight. 
 Perform shut down procedure after last run. 
 
4.9.2 Review quality control data 
Compare quality control values against the ranges provided in the kit.  Note 
any values that are out of range when sending results to FHI 360. 
 
4.9.3 Export data 
 74 
Export to Excel and select “multiple analyte” and save to hard drive. 
 
4.9.4 Wash between plates 
 
To wash the fluidics lines between each plate reading to prevent traces of 
sample or other debris from building up inside the system. 
 
 This actions needs to be done before each new plate reading is 
started.  
 Click “Wash Between Plates” button and follow on screen instructions; by filling 
the 10% isopropanol and deionized water reservoirs to run the procedure.  Eject 
plate holder, insert (MCV) calibration plate and click “OK”. 
 
4.10 Shut down procedure 
 
 Click “Shut down” and follow on screen instructions; by filling the 10% bleach and 
deionized water reservoirs to run the shut down procedure.  Eject plate holder, insert 
calibration plate and click “OK”. 
 Turn off Bio-Plex 200 system (two switches) and switch off the PC. 
 Empty waste bottle. Recap the bottle and close firmly. 
 Fill sheath fluid bottle to fill line if needed. Recap the bottle and close firmly. 
 Wash calibration plate (i.e. MVC plate) by running water over plate at an angle.  
 Dry plate and return to storage compartment of the Bio-Plex 200 system. 
 
5 Quality control 
 
5.1 Internal quality control 
 Send standard curve data to Lindi Roberts for quality assurance review. 
 
9 Reporting 
 All raw data is send to Jen Deese (FHI) for further analysis.  
 
10 Storage of samples 
 Aliquots of PBS are stored at -80°C ± 5°C as long as needed for the study. 
  
11 Training 
 The trainee follows the complete procedures with an experienced person and then 
makes an analysis on a blind panel. 
  
14 Safety and environment 
 See WebIso: safety and environment 
  
15 Attachments and forms for completion 
  Worksheet Human Cytokine/Chemokine Magnetic Bead Assay 
 MILLIPLEX MAP Kit: Human Cytokine/Chemokine Magnetic Bead Panel 
 
16 Revision 
Changes with respect to 
the previous published 
version: 
New Sop 
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 17 Approval and distribution 
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Initiated by: Jen Deese  
Lindi Roberts  
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